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CANADIAN PHARMACIES: A PRESCRIPTION FOR A
PUBLIC HEALTH DISASTER
It began as a novelty: grannies riding buses to Canada in search of
cheaper medicines. But today, that search has mushroomed into a
cross-border war that pits desperate consumers and defiant state
and local governments against the powerful pharmaceutical indus-
try and the Bush administration.1
INTRODUCTION
Prescription drug costs in America have reached record prices.2
Americans pay more for prescription drugs than citizens of any other
country. 3 To make matters worse, the cost of prescription drugs is
increasing faster than ever.4 Since 1998, drug prices have increased at
a rate that is more than double the rate of inflation.5 These increas-
ingly high prices are creating a nationwide epidemic of Americans
who are unable to afford the medications they need.6
In response to the rising cost of prescription drugs, many Americans
are turning to Canada for a solution.7 Some people take bus trips into
Canada to get their prescriptions filled.8 More commonly, Americans
just turn on their computers and order the medications online from
Canadian pharmacies. 9 Canadian pharmacies supply Americans with
prescription drugs from Canada by mail.10 Any American can fax a
prescription to Canada where a Canadian pharmacist reviews and re-
writes the prescription, fills it, and ships it back.1' These Canadian
1. William M. Welch, Seniors Seek Bargains; FDA Cracks Down, USA TODAY, Oct. 7, 2003, at
1A.
2. See Public Health Association of New York City (PHANYC) Policy Statements, Making
Medicines Affordable: The Price Factor (May 9, 2000), at http://www.phanyc.org/affordable.
html.
3. Welch, supra note 1.
4. PHANYC Policy Statements, supra note 2.
5. Danielle Deaver & Kristi E. Swartz, Hard To Swallow Ad Costs Help Put Drug Prices Out
of Reach for Some, WINSTON-SALEM J., Apr. 27, 2003, at Al.
6. Welch, supra note 1.
7. Although this Comment will focus on reimportation from Canada, Americans are also ob-
taining prescription drugs from other countries such as Mexico. See generally Donald E. deKief-
fer, The Mexican Drug Connection: How Trade in Pharmaceuticals Has Wrecked the FDA, 9 Sw.
J. L. & TRADE AM. 321 (2003).
8. Welch, supra note 1.
9. Id.
10. For an example of a Canadian pharmacy, see CanaRx Services, Inc. (CanaRx), at http://
www.CanaRx.com (last visited Oct. 21, 2004).
11. See infra notes 128-140 and accompanying text.
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pharmacies take orders over the internet and mail the drug orders to
American consumers. 12
The practice of importing drugs across the border from Canada is
known as reimportation. t 3 Many of these drugs are originally manu-
factured by American pharmaceutical companies and distributed to
Canadian pharmacies. 14 The Federal Food, Drug, and Cosmetic Act
(FFDCA) expressly prohibits reimportation. 15 Although currently il-
legal, reimporting prescription drugs across the border 16 is a rapidly
growing enterprise. In 2000, the importation of prescription drugs
from Canada constituted a business of just a few million dollars per
year.17 By contrast, in 2003, the amount of reimportation activity was
predicted to be $800 million. 18
The numbers are shocking. Consumers can save between 32% and
57% on commonly purchased prescription drugs by purchasing them
from an online Canadian pharmacy. 19 For example, a person can
purchase Celebrex 20 from the Canadian pharmacy CanaRx Services,
Inc. (CanaRx) for more than 50% less than at Walgreens. Specifically,
CanaRx sells 100 mg pills in quantities of 300 for $218.90,21 where
Walgreens.com sells the same quantity of Celebrex pills for $564.95.22
Mark McClellan, former Commissioner of the Food and Drug Ad-
ministration (FDA) has said, "we are enforcing the law,"'23 but to date,
only one Canadian pharmacy, Rx Depot, Inc. (Rx Depot) has been
12. See infra notes 128-140 and accompanying text.
13. Michael Dickson, International Pharmaceutical Expenditure Differentials: Why?, in Sup-
PLEMENT TO MANAGED CARE: REIMPORTATION OF PHARMACEUTICALS: ECONOMIC AND POL-
ICY IMPLICATIONS 3 n.1 (March 2004), available at http://www.managedcaremag.com/
supplements/0403_reimport/MC_0403_reimpor tsuppl.pdf.
14. See Jerry Stanton, Comment, Lesson for the United States from Foreign Price Controls on
Pharmaceuticals, 16 CONN. J. INT'L L. 149, 153 (2000) (explaining that "the vast majority of
biotech today is located within the United States" and that "[t]he American pharmaceutical
industry is the undisputed world leader in developing new and effective treatments").
15. 21 U.S.C. § 381(d)(1) (2000).
16. Id.
17. Welch, supra note 1.
18. Id.
19. Tim Jones, Seniors Find Canada Is Refuge from Drug Prices: U.S. Costs Leave No Choice,
They Say, CHI. TRIB., Sept. 21, 2003, § 1, at I (including a chart comparing U.S. drug prices with
the price for the same drug from a Canadian pharmacy).
20. Celebrex is a well-known prescription drug made by Searle and Pfizer and is prescribed
for the treatment of arthritis and to reduce other forms of pain and swelling. See Celebrex
Website, at http://www.celebrex.com (last visited Oct. 25, 2004).
21. CanaRx, Medications List, at http://www.CanaRx.com/Store/MedicationsList.htm (last
modified Oct. 12, 2004) (listing the company's drug prices in U.S. dollars for sale to Americans).
22. Walgreens Pharmacy Website, at http://www.walgreens.com/library/finddrug/druginfol.
jhtml?=id=15101 (last visited Oct. 25, 2004) (listing Celebrex 100 mg capsules at $112.99 for a
container of 60 capsules).
23. Welch, supra note 1.
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shut down.2 4 The FDA has also sent warning letters to other Cana-
dian pharmacies, 25 but at this time it is too early to tell what the fate
of Canadian pharmacies will be. Regardless of federal regulations
prohibiting reimportation, many state and local politicians are seeking
to begin reimportation programs for their constituents and individual
consumers are already reimporting their medications in record
numbers.
At the center of the reimportation issue is one piece of federal legis-
lation. The United States House of Representatives passed the Phar-
maceutical Market Access Act of 2003, H.R. 2427 (H.R. 2427)26 on
July 25, 2003.27 If enacted into law, this bill would legalize reimporta-
tion of prescription drugs from twenty-six countries and remove the
requirement that the Secretary of the Department of Health and
Human Services (HHS) certify the safety of imported drugs.28 This
bill is becoming an important health care issue with tensions rising
among the pharmaceutical industry, the FDA, Canadians, state and
federal governments, and Americans who cannot afford their
medication.
This Comment will demonstrate why Congress should not pass H.R.
2427 to legalize reimportation of prescription drugs from Canada.
Part II of this Comment provides the detailed background necessary
to analyze the problem of reimporting prescription drugs including de-
scriptions of the following: (1) the Canadian and American health
care systems; (2) the way prescription drugs are priced and regulated
in each country; (3) the way in which Canadian pharmacies operate;
and (4) the current American law regarding reimportation. 29 Part III
discusses the views of all groups interested in the reimportation issue
and introduces H.R. 2427.30 Part IV explores alternatives to import-
ing prescription drugs from Canada. 31 Finally, Part V concludes that
legalizing reimportation is not an adequate solution to the rising costs
24. See United States v. Rx Depot, Inc., 290 F. Supp. 2d 1238 (N.D. Okla. 2003).
25. See infra notes 157-162 and accompanying text.
26. H.R. 2427, 108th Cong. (2003). The Senate counterpart to H.R. 2427 is S. 1781. See S.
1781, 108th Cong. (2003). H.R. 2427 is the primary bill regarding legalizing reimportation.
However, another bill addressing reimportation was recently introduced in the senate. See The
Pharmaceutical Market Access and Drug Safety Act of 2004, S. 2328, 108th Cong.
27. House Approves Reimportation; Senate Stands Against It, WASH. DRUG LETrER, Aug. 4,
2003, 2003 WL 10134747 (explaining that the House approved H.R. 2427 by a vote of 243-186).
28. See H.R. 2427.
29. See infra notes 33-212 and accompanying text.
30. See infra notes 213-319 and accompanying text.
31. See infra notes 320-389 and accompanying text.
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of prescription drugs and suggests that the best solution is for the
United States to adopt its own system of price controls.32
II. BACKGROUND
The soaring costs of prescription drugs in the United States and the
affordability of these same drugs in Canada are driving Americans to
purchase prescription drugs from online Canadian pharmacies. 33 The
problem surrounding the Canadian pharmacies controversy is com-
plex, and for an effective analysis of the legal issues surrounding this
controversy, it is necessary to understand the health care systems in
the United States and Canada. Accordingly, this section will briefly
compare those health care systems and examine the pricing and regu-
lation of prescription drugs in both countries. The types of Canadian
pharmacies and the way in which Canadian pharmacies conduct busi-
ness will also be addressed. Finally, this section will explain the cur-
rent law on reimporting prescription drugs and introduce the most
recent case in this area of law, United States v. Rx Depot, Inc. 34
A. A Comparison of U.S. and Canadian Health Care Systems
Americans purchase prescription drugs from Canadian pharmacies
because they are cheaper than drugs available in the United States. 35
A comparison of the United States health care system to the health
care systems in other countries reveals that Americans pay more for
health care than anyone else in the world, not just Canada. 36 Under-
standing the basic differences between the health care systems of the
United States and Canada is essential to analyzing the soaring costs of
prescription drugs and the reimportation problem.
32. See infra Part V.
33. See Welch, supra note 1.
34. 290 F. Supp. 2d 1238 (N.D. Okla. 2003)
35. Welch, supra note 1. See also Andrew Harris, Comment, Recent Congressional Responses
to Demands for Affordable Pharmaceuticals, 16 Loy. CONSUMER L. REV. 219, 227-29 (2004);
Jane Bryant Quinn, A Remedy for Pricey Drugs, NEWSWEEK, Sept. 27, 2004, at 31, 31; Vicki
Kemper, Importing Drugs Seen as a Way to Lower Costs, L.A. TIMES, Mar. 20, 2004, at 23A.
36. See, e.g., HANDBOOK OF INTERNATIONAL HEALTH CARE SYSTEMS 118 (Khi V. Thai et al.
eds., 2002) [hereinafter HANDBOOK]; HEALTH CARE DELIVERY IN THE UNITED STATES 4
(Anthony R. Kovner & Steven Jonas, eds., 7th ed. 2002) [hereinafter HEALTH CARE DELIVERY];
Michele L. Creech, Comment, Make a Run For the Border: Why the United States Government Is
Looking to the International Market for Affordable Prescription Drugs, 15 EMORY INT'L L. REV.
593, 612 (2001).
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1. The U.S. Health Care System
The U.S. health care system is essentially a free market system.37
Health care in the United States is a mostly privatized regime where
citizens pay for their own privately financed and privately delivered
health care programs and services.38 America's health care system is
a complex and loosely structured system that has even been described
as a "non-system. ' 39 The complexity of the United States's system
stems from a number of factors, including the country's population, its
geographic size, the variety of methods available for providing health
care services, managed care influences, and the challenges of financing
health care.40 Most health care coverage in America is provided
through voluntary employer programs for employees and their depen-
dents.41 Government programs are generally limited to the poor,
aged, and disabled.42 Although many Americans have the option of
health care insurance through an employer program or a federally
funded program, a significant number of Americans do not have ac-
cess to any health insurance. 43
Medicare and Medicaid are the two major federally funded pro-
grams in the American health care system.44 These two programs are
also important to the issue of drug reimportation because many senior
citizens receive the benefits of Medicare or Medicaid. 45 Medicare is a
37. Creech, supra note 36, at 596.
38. Nicole A. Rothstein, Comment, Protecting Privacy and Enabling Pharmaceutical Sales on
the Internet: A Comparative Analysis of the United States and Canada, 53 FED. COMM. L.J. 343,
366 (2001).
39. HANDBOOK, supra note 36, at 135 (describing the U.S. health care system as a colander, a
leaky vessel being plugged one hole at a time). However the system is characterized or criti-
cized, the American health care system provides the most cutting-edge technology, has the high-
est paid doctors, and has the most expensive hospitals in the world. HEALTH CARE DELIVERY,
supra note 36, at 4; see also HANDBOOK, supra note 36, at 118.
40. See generally HANDBOOK, supra note 36. The private-public system of reimbursement for
health care services is particularly complicated. Physicians can be reimbursed by a fee for ser-
vice arrangement, salary, or prepayment. Id. at 121. This system is further complicated by the
plethora of players in the insurance system and bureaucracy at all levels. See id. at 118-22.
41. Id. at 125. In 1995, about 70% of U.S. citizens were covered by private health insurance,
and 85% of these individuals were insured through work-related insurance plans. Id. at 119.
42. Id. at 125.
43. HANDBOOK, supra note 36, at 124. In 1993, there were 39.7 million Americans, 15.3% of
the population, without health insurance. Id. In 1995, there were 40.3 million Americans, 17.4%
of the population, without health insurance. Id. at 124.
44. HEALTH CARE DELIVERY, supra note 36, at 50 (stating that "[i]n 1997, Medicare and
Medicaid accounted for 83.5% of public outlays for personal health care services").
45. See generally Centers for Medicare and Medicaid Services (CMS), Medicaid Home Page,
at http://cms.hhs.gov/medicaid (last modified Sept. 16, 2004); CMS, Medicare Home Page, at
http://cms.hhs.gov/medicare (last modified Sept. 16, 2004). Medicare is specifically directed at
those aged sixty-five and older. CMS, Medicare Home Page, supra. Senior citizens with low-
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health insurance program that originated in 1966 and provides medi-
cal care benefits for citizens age sixty-five and older, disabled persons
and their dependents, or those suffering from chronic kidney dis-
ease.4 6 Medicaid, on the other hand, is a program run by federal and
state governments together and provides medical assistance for cer-
tain individuals and families with low incomes. 47 Although the federal
government has established guidelines for eligibility, Medicaid eligi-
bility requirements are determined by each state.48 Thus, whether a
person will be eligible for Medicaid depends on the requirements of
the state where she lives.49
Unfortunately, the trend in American health care is to decrease ac-
cess to services and raise the cost of treatment. 50 Americans spend
more on health care than do the people of any other country.51 Fur-
thermore, in 1995, 9% of the total expenditures allocated to health
care were devoted to pharmaceuticals. 52 Even if a person has health
insurance, the insurance typically will cover less than 100% of the
drug costs. 53 In 1992, governmental and private health insurers cov-
ered 96% of hospital services and 82% of physician services, but only
covered 72% of the cost of pharmaceuticals. 54 Because many senior
citizens require a significant number of prescription drugs, the rising
cost of prescription drugs impacts them more than any other category
of citizens in America. 55
incomes are eligible for Medicaid. CMS, Medicaid Home Page, supra. Therefore, these two
programs are significant sources of health insurance coverage for senior citizens.
46. HEALTH CARE DELIVERY, supra note 36, at 47-49.
47. CMS, Medicaid Home Page, supra note 45.
48. CMS, Medicaid Site for State & Territorial Government Information, at http://www.
cms.hhs.gov/states/default.asp (last modified Sept. 16, 2004). The federal guidelines provide
Medicaid eligibility to the following: low-income families with children, Supplemental Security
Income (SSI) recipients, infants born to Medicaid-eligible women, children under age nineteen,
pregnant women whose family income is at or below 133% of the federal poverty level, recipi-
ents of adoption assistance and foster care subsidies, and specially protected groups that may
keep Medicaid for a limited period of time, such as people who lose Medicaid coverage due to
loss of SSI payments or increased wages. CMS, Medicaid Eligibility, at http://cms.hhs.gov/medi-
caid/eligibility/criteria.asp (last modified Sept. 16, 2004) (explaining Medicaid eligibility require-
ments). States have discretion to allow Medicaid coverage for "categorically needy" people who
share the characteristics of the mandatory groups. Id.
49. CMS, Medicaid Site for State & Territorial Government Information, supra note 48.
50. HANDBOOK, supra note 36, at 137.
51. Stephen R. Latham, Pharmaceutical Costs: An Overview and Analysis of Legal and Policy
Responses by the States, 24 J. LEGAL MED. 141, 141 (2003) (explaining that in 2001 Americans
spent $140.6 billion on outpatient prescription drugs).
52. HANDBOOK, supra note 36, at 121.
53. Id.
54. Id. at 121-22.
55. Welch, supra note 1.
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2. The Canadian Health Care System
In contrast to the U.S. health care system, the Canadian health care
system is publicly financed but privately delivered.5 6 Canada's system,
known as Medicare, provides universal coverage to all Canadian re-
sidents.57 Canadian Medicare covers hospital and physician services
that are medically necessary. 58 Each Canadian province provides a
health care plan that must meet criteria set forth in the 1984 Canada
Health Act.59 The delivery of health care is carried out by the private
sector, including not-for-profit hospitals and physicians that are solo
practitioners. 60 Thus, the insurance system in Canada is socialized,
but health care delivery remains privately administered.
61
Whereas the U.S. system is primarily privately financed, 62 Canada's
health care system is financed by five different sources: the federal
government, provinces, local government, workers compensation
boards, and private sources. 63 Although money comes from all of
these five sources, the majority of Canada's health care dollars come
from the federal government and the provinces, through individual
and corporate taxes. 64 The federal government also pays provinces on
a per capita rate.65 This rate is tied to the growth of the economy, as
measured by the country's gross domestic product.
66
Americans have demonstrated interest in adopting a system similar
to Canada's, 67 but the Canadian system is not flawless.68 Beginning in
the 1980s, Canada began to experience problems with budget cuts,
hospital closings and staff reductions, and delays or waiting lists for
health care services. 69 Since the 1980s, the increasing federal budget
deficit decreased spending on health care.70 This left the provinces to
bear more of the health care costs, but the provinces were experienc-
56. Rothstein, supra note 38, at 366.
57. JANE FULTON, CANADA'S HEALTH SYSTEM: BORDERING ON THE POSSIBLE 2 (1993). Ca-
nadian Medicare arose out of political tensions surrounding the need for publicly financed health
care insurance and was eventually implemented in every Canadian province by 1971. Id.
58. HANDBOOK, supra note 36, at 81.
59. Id.
60. Id. at 82.
61. Id.
62. See supra notes 37-55 and accompanying text.
63. FULTON, supra note 57, at 27.
64. See id; HANDBOOK, supra note 36, at 84.
65. HANDBOOK, supra note 36, at 80-81.
66. Id. at 84.
67. Id. at 88.
68. Id. at 87-92.
69. Id.
70. Id. at 89-90.
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ing budget deficits of their own.71 The lack of sufficient funding re-
sulted in hospital closings and staff reductions. 72 These budget cuts,
hospital closings, and staff reductions have led to waiting lists and de-
lays in service. 73 For example, hospitals have set limits on the number
of procedures they will perform each year due to budget constraints,
and the patient waiting time has substantially increased.74
B. A Comparison of Pricing and Regulation of Prescription Drugs
in the United States and Canada
A comparison of pharmaceutical regulation and pricing systems in
the United States and Canada reveals some similarities as well as a
number of differences. 75 While both countries protect public health
and safety through federal regulations of food and drug products,
pharmaceuticals are priced very differently in each country.76 While
pharmaceutical companies in the United States determine the price of
prescription drugs, pharmaceutical prices in Canada are subject to
federal price controls.77
1. Pricing and Regulation of Prescription Drugs in the United States
Pharmaceutical companies set the prices of prescription drugs in the
United States.78 These companies have broad discretion to price
drugs at whatever levels the market will allow. 79 Factors that contrib-
ute to the cost of drugs in the United States include research and de-
velopment (R&D) expenditures, access to the newest technology,
patent protection, an increase in drug use, marketing expenses, and
lobbying expenses.80 In short, prescription drug prices in the United
States are high to offset the huge expenditures that pharmaceutical
companies spend on developing and marketing their products.81
71. HANDBOOK, supra note 36, at 89-90.
72. Id. at 90-91 (with a large increase in the number of doctors migrating to the United
States).
73. Id. at 91-92.
74. Id.
75. See Patricia I. Carter, Federal Regulation of Pharmaceuticals in the United States and Ca-
nada, 21 Loy. L.A. INT'L & COMP. L.J. 215, 220-58 (1999). Carter's article compares the U.S.
and Canadian systems' regulation and pricing of prescription drugs. Id.
76. See Creech, supra note 36, at 596-625 (discussing regulation and pricing of prescription
drugs in various countries).
77. Id.
78. Id. at 600-12 (discussing factors that affect the price of drugs in the United States).
79. Id. at 596.
80. Id. at 600-10.
81. Id. at 596-612.
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While pharmaceutical companies boast profit margins averaging
nearly four times that of the average Fortune 500 company,82 this in-
dustry is distinct from other industries.83 While pharmaceutical com-
panies seem to be incredibly profitable, enjoying the benefits of sales
at high prices, in reality these companies are not as profitable as they
seem.84 Empirical studies have revealed that "the pharmaceutical in-
dustry's profitability is within 1% of its real cost of capital, clearly not
an excessive level of profitability. ' 85 Pharmaceutical companies spend
a considerable amount on R&D, but not every drug developed can
recoup the costs incurred to bring it to market. 86 In addition to R&D
expenditures, marketing costs must also be factored into the ultimate
cost of drugs.87 Furthermore, there is a long lag time between the
initial investment in developing a drug and the time when the com-
pany makes money on the drug.88 The development of a drug also
requires a high amount of sunk costs, 89 which these companies must
eventually recover.90
Although drug manufacturers determine the price of prescription
drugs based on what the market will allow, pricing is not based on
supply and demand.9t Since consumers are not free to choose which
drugs to purchase, comparison shopping is not feasible, and insurance
companies (who are the ultimate purchasers of drugs for their in-
sureds) have nothing to do with determining which drugs are pre-
scribed and at which prices they are available, the pharmaceutical
industry is not subject to free market forces.92 Moreover, the reality is
82. Not all pharmaceutical companies are profitable. Stanton, supra note 14, at 153. In fact,
only 14 of the 260 publicly traded biotech companies are profitable. Id.
83. Id. at 154-57.
84. Id.
85. Id. at 156.
86. "On average only 3 out of every 10 prescription drugs available to treat Americans gener-
ate revenues that meet or exceed average R&D costs." PHARMACEUTICAL RESEARCH & MANU-
FAcTURERS OF AM. (PhRMA), WHY DO PRESCRIPTION DRUGS COST So MUCH ... AND OTHER
QUESTIONS ABOUT YOUR MEDICINES 2 (June 2000), http://www.phrma.org/publications/publica-
tions/brochure/questions/questions.pdf.
87. See Harris, supra note 35, at 225-26 (discussing how the pharmaceutical industry is im-
pacted when marketing budgets exceed research and development (R&D) budgets).
88. Id. (explaining that it takes ten to twelve years on average to develop a drug).
89. Sunk costs are those "incurred in preparing to bring a product to market, and are largely
unrecoverable once spent." Stanton, supra note 14, at 155. Sunk costs include R&D, efficacy
studies, and time delays due to experimentation and approval processes. Id.
90. Id.
91. Michael B. Moore, Comment, "Open Wide" (Your Pocketbook That Is!) - A Call for the
Establishment in the United States of a Prescription Drug Price Regulatory Agency, 1 Sw. J. L. &
TRADE AM. 149, 154-55 (1994).
92. Id.
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that certain drugs are priced much higher than the costs to bring them
to market.93
In the United States, the FDA is the federal agency charged with
regulating the safety and efficacy of prescription drugs.94 It has be-
come a "direct regulator of industry through issuance of substantive
rule, screening of new products for safety and effectiveness prior to
marketing, and adjudication of a broad range of formal and informal
proceedings subject only to limited review by courts. ' 95 The statute
currently governing this area is the FFDCA, which is the statute that
regulates food, over-the-counter drugs, prescription drugs, and
cosmetics. 96
U.S. Customs also works with the FDA in investigating violations of
public health and safety laws.97 Customs ensures that all imports and
exports comply with U.S. laws and regulations. 98 Customs has the au-
thority to intercept illegal importation, exportation, and trans-ship-
93. See Latham, supra note 51, at 147 (arguing that it is not unfair that Americans pay more
for prescription drugs than people in other countries). Latham explains that (1) liability for drug
manufacturing in the United States is higher than in other countries due to the litigious nature of
the country, (2) other countries have health systems that function as monopsony buyers of drugs,
able to negotiate lower prices, (3) the United States has a large economy that is not as price-
sensitive as countries with smaller economies overall, and (4) it is cheaper for pharmaceutical
companies to grant concessions to small foreign buyers of pharmaceuticals than it is to grant
concessions to U.S. buyers. Id.
94. The Mission Statement of the U.S Food and Drug Administration (FDA) is:
The FDA is responsible for protecting the public health by assuring the safety, efficacy,
and security of human and veterinary drugs, biological products, medical devices, our
nation's food supply, cosmetics, and products that emit radiation. The FDA is also re-
sponsible for advancing the public health by helping to speed innovations that make
medicines and foods more effective, safer, and more affordable; and helping the public
get the accurate, science-based information they need to use medicines and foods to
improve their health.
FDA, FDA's Mission Statement, at http://www.fda.gov/opacom/morechoices/mission.html (last
visited Oct. 28, 2004).
95. Fooo AND DRUG LAW 1 (Richard M. Cooper ed., 1991).
96. 21 U.S.C. §§ 301-399 (2000).
97. See Press Release, U.S. Food and Drug Administration, FDA/U.S Customs Import Blitz
Exams Reveal Hundreds of Potentially Dangerous Imported Drug Shipments (Oct. 1, 2003), at
http://www.cbp.gov/xp/cgov/newsroom/press-releases/archives/cbp-press-releases/0102003/
10012003.xml. See also Ivette P. Gomez, Note, Beyond the Neighborhood Drugstore: U.S. Regu-
lation of Online Prescription Drug Sales by Foreign Businesses, 28 RUTGERS COMPUTER & TECH.
L.J. 431, 439 (2002) (explaining that the FDA has partnered with such agencies as Customs, the
Department of Justice, the Federal Bureau of Investigation (FBI), and the Postal Inspection
Service to oversee regulation of drug importation into the United States).
98. U.S. Customs & Border Protection, U.S. Customs Service - Over 200 Years of History, at
http://www.cbp.gov/xp/cgov/toolbox/about/history/history.xml (last visited Oct. 25, 2004) (detail-
ing over 200 years of history of the organization).
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ment of products that may jeopardize public health and safety,
including the types of drugs being imported from Canada. 99
2. Pricing and Regulation of Prescription Drugs in Canada
Unlike the U.S. government, the Canadian government sets price
controls to regulate the cost of prescription drugs. 100 Although the
Canadian system of pricing pharmaceuticals differs greatly from that
of the U.S. system, the Canadian government also has a federal
agency that regulates the pharmaceutical industry.
In contrast to the United States, Canada has federal price con-
trols. 01 Over the years, Canada has experimented with various meth-
ods of price controls. 102 In 1968, the prices Canadians were paying for
prescription drugs were among the highest in the world.10 3 As a re-
sult, the Canadian government enacted legislation that mandated li-
censing of patented drugs to manufacturers. 10 4 In 1987, in response to
concerns that patentee's rights were being undermined by the
mandatory patent licensing law, Canada amended its patent act to
guarantee exclusivity to the patentee for the first seven years of the
patent's term before mandatory licensing could be imposed.'0 5 Antic-
ipating the North American Free Trade Agreement, which eliminated
compulsory licensing and imposed a twenty-year patent term, Canada
established the Patented Medicines Prices Review Board (PMPRB) in
1987 and expanded its powers in 1993.106
Under the current method of price regulation, the PMPRB regu-
lates prices of all pharmaceuticals. 10 7 The PMPRB sets a maximum
price for each drug based on the average price of the drug in seven
other developed countries. 108 The price of any given drug may fluctu-
99. See U.S. Immigration & Customs Enforcement: Smuggling/Public Safety Division Web-
site, at http://www.ice.gov/graphics/investigations/publicsafety/index.htm (last visited Oct. 25,
2004).
100. Stanton, supra note 14, at 160.
101. Id. at 167. In fact, most of the industrialized world (including Germany, Japan. and
France), imposes price controls on pharmaceuticals. Id. at 160-65.
102. Id. at 160.
103. Id.
104. Id.
105. Stanton, supra note 14, at 160.
106. Id.
107. Creech, supra note 36, at 615. The Patented Medicines Prices Review Board (PMPRB)
is "a quasi-judicial body, protects consumers and contributes to health care by ensuring that the
manufacturers' prices of patented medicines are not excessive." Health Canada Home Page, at
http://www.hc-sc.gc.ca/english/about/org.html#la (last modified Sept. 24, 2004) (describing the
various responsibilities of groups within the Health Canada organization).
108. Creech, supra note 36, at 615. The seven other countries are: France, Germany, Italy,
Sweden, Switzerland, the United Kingdom, and the United States. Id. at 615 n.121.
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ate within the Canadian Consumer Pricing Index,109 but may not ex-
ceed the price established by PMPRB.1 10 In addition, the PMPRB
also compares the price of new drugs to medicines already available in
Canada and may ask manufacturers to lower prices, pay fines, or re-
turn excess revenues if the price of a particular drug becomes too
high." ' Most manufacturers voluntarily comply with the PMPRB's
requests for price reductions, but the PMPRB does have the authority
to enforce compliance through formal hearings." 2 Thus, the prices of
prescription drugs in Canada are significantly lower than the prices of
the same drugs in the United States.
Although extremely attractive, lower prescription drug prices do
not come without consequences."13 One significant problem that
Canadians face is that the newest, cutting-edge drugs are not available
in Canada until well after they are available in the United States. 1 4
To keep drug prices low, Canadian health officials delay approval and
introduction of new and more expensive drugs." 5 Although U.S. poli-
ticians and media focus on stories of Americans seeking prescription
drugs from Canada, Canadians have also been coming to the United
States to buy prescription drugs.1 6
Similar to the United States's FDA, Canada has an administrative
program to ensure the safety of prescription drugs. In response to
concerns about inadequate clinical testing of drugs for human use, the
Canadian Parliament enacted the Food and Drugs Act in 1951.117
This statute required that information about new drugs be submitted
109. The Statistics Canada website explains in detail what the Canadian Consumer Price In-
dex is:
The Consumer Price Index (CPI) is an indicator of changes in consumer prices exper-
ienced by Canadians. It is obtained by comparing through time, the cost of a fixed
basket of commodities purchased by consumers. Since the basket contains commodities
of unchanging or equivalent quantity and quality, the index reflects only pure price
movements....
The CPI is widely used as an indicator of the change in the general level of consumer
prices or the rate of inflation.
Statistics Canada, Consumer Price Index, at http://www.statcan.ca/english/sdds/2301.htm (last
visited Oct. 25, 2004).
110. Creech, supra note 36, at 615.
111. Id.
112. Stanton, supra note 14, at 161 (explaining that the PMPRB has withstood legal chal-
lenges to its authority and jurisdiction).
113. Sally C. Pipes, Cheaper Doesn't Mean Better. Ask a Canadian, WASH. POST, Sept. 21,
2003, at B-3.
114. Id.
115. Id.
116. Id.
117. Carter, supra note 75, at 219.
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to the Food and Drugs Division of the Department of Health and
Welfare, the predecessor of the Health Products and Food Branch
(HPFB). 118 The Canadian Food and Drugs Act provides the frame-
work for regulation of prescription drugs in Canada.
The Canadian equivalent to the FDA is Health Canada.1 19 The or-
ganization within Health Canada that is responsible for the regulation
of pharmaceuticals is the HPFB. 120 Similar to the Food and Drug
Commissioner in the United States, Canada has a Minister of
Health. 21 The PMPRB and HPFB, among others, report to the Ca-
nadian Parliament through the Minister of Health. 22 Also like the
FDA, Health Canada regulates a broad array of health issues includ-
ing pharmaceuticals, food, the environment, and agricultural health
issues. 123 Structured as a branch of Health Canada, the HPFB is the
organization "responsible for evaluating, regulating and monitoring
drugs, biologics, and medical devices."'1 24 In addition to regulating
food and health products, the HPFB oversees food and natural health
products and promotes good nutrition among Canadian citizens.
1 25
C. How Canadian Pharmacies Work
Cyberspace has changed the way people shop.126 Consumers armed
with virtual shopping carts can purchase just about anything online,
including books, clothing, and now-prescription drugs.127 The typi-
118. Id.
119. See Health Canada Website, at http://www.hc-sc.gc.ca/english/about/about.html (last
modified Mar. 3, 2003). The mission and vision of Health Canada is the following: "Health
Canada is the federal department responsible for helping the people of Canada maintain and
improve their health. Health Canada is committed to improving the lives of all Canada's people
and to making this population among the healthiest in the world." Id.
120. Health Products and Food Branch, Welcome, at http://www.hc-sc.gc.ca/hpfb-dgpsa/in-
dex e.html (last modified Oct. 26, 2004).
121. The Minister of Health at the time of writing is The Honourable Ujjal Dosanjh. See
Health Canada, Health Minister, at http://www.hc-sc.gc.ca/english/media/minister/index.html
(last modified Oct. 25, 2004) (providing the biography of the current Minister of Health).
122. Devidas Menon, Pharmaceutical Cost Control in Canada: Does it Work?, HEALTH AF-
FAIRS, May-June 2001, at 92, 93. See also Health Canada Home Page, Online Organizational
Chart, at http://www.hc-sc.gc.ca/english/about/org.html (last modified Sept. 24, 2004) (providing
the organizational chart of Health Canada).
123. See Health Canada Home Page, at http://www.hc-sc.gc.ca/english/index.html (last modi-
fied Oct. 27, 2004).
124. HEALTH PRODUCTS & FOOD BRANCH, YOUR HEALTH & SAFETY: OUR PRIORITY, http:I/
www.hc-sc.gc.ca/hpfb-dgpsa/your-health-e.pdf (last modified Dec. 31, 2002) (describing the role
of the Health Products and Food Branch (HPFB)).
125. Id. See also HPFB, About Us, at http://www.hc-sc.gc.ca/hpfb-dgpsa/aboutus-e.html (last
modified Apr. 13, 2004).
126. Cybermedicine: The Benefits and Risks of Purchasing Drugs over The Internet, 5 J. TECH.
L. & POL'Y 1, 1 (2000) (explaining the widespread growth of the internet and "e-commerce").
127. See id.
2005]
DEPAUL LAW REVIEW
cal corner drugstore is no longer the only way for people to fill their
prescriptions. A comparison of the Canadian pharmacies available to
Americans reveals that there are two types of Canadian pharmacies:(1) American companies that function as a local storefront of a Cana-
dian pharmacy;1 28 and (2) Canadian pharmacies operating from Ca-
nada via websites. 129
1. American Storefront Canadian Pharmacies
The first type of Canadian pharmacy is the American company that
acts as a local storefront of a Canadian pharmacy, serving customers
by facilitating the reimportation of prescription drugs from Canada. 130
For example, Canada Drug Service is a franchise based in Naples,
Florida with storefronts across the country.13' Each location serves its
customers by helping customers place orders for prescription drugs
from Canadian pharmacies.132 Customers of storefronts bring their
written prescription to the store and fill out a medical question-
naire. 133 Storefronts then fax the prescription to one of seven Cana-
dian pharmacies in British Columbia where a Canadian physician
signs the prescription; the prescription is filled and then mailed di-
rectly to the customer. 134
2. Website Pharmacies Operating From Canada
The second type of Canadian pharmacy consists of pharmacies that
are located in and operate from Canada, taking orders through a web-
site or a toll free telephone number.135 For example, to purchase from
128. Julie Appleby, Firm Fights for Canadian Drugs, USA TODAY, Oct. 7, 2003, at 3B.
129. See infra note 135 and accompanying text.
130. Appleby, supra note 128 (discussing how Rx Depot, Inc. (Rx Depot) serves its customers
and explaining the lawsuit pending against them). Local storefronts such as Rx Depot have also
been dubbed "facilitators" by the National Association of Boards of Pharmacy (NABP). NABP,
POSITION PAPER ON THE IMPORTATION OF FOREIGN PRESCRIPTION DRUGS 2 (Mar. 2003), http://
www.nabp.net/ftpfiles/NABPOI/foreigndrug.pdf [hereinafter NABP POSITION PAPER]. The
NABP states that "[allthough these operations, which range from Internet sites to store fronts,
do not stock or dispense drugs, it is the position of the NABP that they are conducting the
practice of pharmacy and must be appropriately licensed by the state board of pharmacy." Id.
131. Appleby, supra note 128. See also Kelly A. Young, Business Provides Link to Canadian
Drug: Mount Pleasant Operation That Brokers Prescriptions Is Fourth to Open in State, MiLWAU-
KEE J. SENTINEL, Nov. 9, 2003, at 5Z (describing operations of Canada Drug Service in
Wisconsin).
132. Appleby, supra note 128; Young, supra note 131.
133. Appleby, supra note 128.
134. Id.
135. An example of a Canadian pharmacy that falls into this category is Medsforless.com,
which operates out of White Rock, British Columbia. See Medsforless.com, How to Order, at
http://www.medsforless.com/howtoorder.htm (last visited Oct. 28, 2004) (explaining the process
for ordering). See also CanadaPharmacy.com, How to Order Prescription Drugs, at http:lwww.
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Universal Drugstore, Ltd. (Universal Drugstore) in Winnipeg, Mani-
toba, the patient mails or faxes her prescription directly to Universal
Drugstore in Winnipeg. 136 Some Canadian pharmacies, such as Uni-
versal Drugstore, also have the patient complete a questionnaire and
release form. 137 Then a Canadian pharmacist contacts the American
customer to review the prescription. 138 The Canadian pharmacist ap-
proves the prescription, 139 and it is mailed directly to the customer.
140
To help inform consumers about the reliability of all types of online
pharmacies, the National Association of Boards of Pharmacy
(NABP) 141 has created the Verified Internet Pharmacy Practice Sites
(VIPPS) program.142 VIPPS was established in the spring of 1999 in
response to a NABP task force recommendation that the internet
pharmacy industry impose self-regulation. 143 Online pharmacies are
entitled to display the VIPPS seal if they are deemed compliant with
NABP standards. 144 Specifically, NABP standards require that the
online pharmacies meet the licensing and inspection requirements of
their state and each state to which they dispense pharmaceuticals.
145
Other VIPPS criteria include "patient rights to privacy, authentication
and security of prescription orders, adherence to a recognized quality
assurance policy, and provision of meaningful consultation between
patients and pharmacists.' 1 46 The VIPPS seal contains a hyperlink to
a website displaying verified information regarding the pharmacy's
canadapharmacy.com/cart/index.cfm?fuseaction=prescriptions (last visited Oct. 28, 2004) (ex-
plaining the procedure of getting an American prescription filled). CanadaPharmacy.com is a
Canadian pharmacy operating out of Surrey, British Columbia. CanadaPharmacy.com, at http://
www.canadapharmacy.com/index.cfm?CFID=3560413&CFTOKEN=50488851t (last visited Oct.
26, 2004).
136. Universal Drugstore. How to Order: Option A, at http://www.universaldrugstore.com/
optionA.asp (last visited Oct. 26, 2004) [hereinafter How to Order: Option A].
137. Id.
138. Id.
139. Universal Drugstore, Customer Service, at http://www.universaldrugstore.com/customer-
service.asp (last visited Oct. 26, 2004).
140. How to Order: Option A, supra note 136.
141. Established in 1904, NABP "assist[s] state licensing boards in developing, implementing,
and enforcing uniform standards to protect the Public Health." NABP Home Page, VIPPS, at
http://www.nabp.net/vipps/intro.asp (last modified Aug. 13, 2004). NABP membership consists
of the pharmacy boards of all fifty states and "the District of Columbia, three U.S. territories,
eight Canadian provinces, [and] two Australian states." Id.
142. See id. (explaining the Verified Internet Pharmacy Practice Sites (VIPPS) program);
Gomez, supra note 97, at 431.
143. See John Michael Ward, Online Pharmaceutical Regulation: An Avenue to a Safer World,
24 J. LEGAL MED. 77 (2003). Part II of Ward's article provides a thorough discussion of the
regulatory scheme of internet pharmacies.
144. See id. Part 11.1.
145. NABP Home Page, VIPPS, supra note 141.
146. Id.
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website and information about the pharmacy.' 47 A survey of Cana-
dian pharmacy websites reveals none that bear the VIPPS seal.' 48
D. The Current Law on Reimportation of Prescription Drugs
The reimportation of prescription drugs from Canada into the
United States is illegal. 149 Reimportation is expressly prohibited by 21
U.S.C. § 381(d)(1). 150 Drugs brought into the United States through
reimportation will likely fail to comply with numerous other laws. 151
Furthermore, Canadian pharmacies, which claim that a personal use
exception allows reimporting prescription drugs, are misleading
American consumers because there is no existing policy to that
effect.152
1. FFD CA, 21 U.S.C. § 381(d)(1)
The FFDCA, Title 21 of the United States Code § 381(d)(1) states
that "except as provided in paragraph (2) and section 384 of this title,
no drug .. .which is manufactured in a State and exported may be
imported into the United States unless the drug is imported by the
manufacturer of the drug."'1 53 Even if a particular drug is FDA-ap-
proved for use in the United States, it is illegal to bring the drug back
into the United States through a Canadian pharmacy. 154
Although reimporting prescription drugs is clearly illegal, this stat-
ute has not been strictly enforced. 155 Due to the increasing attention
given to this issue, the FDA has recently made public statements that
147. See Ward, supra note 143, at Part II.
148. The NABP Website contains a list of VIPPS certified pharmacies; none of them are Ca-
nadian pharmacies. See NABP Website, VIPPS Database Search Results, at http://www.nabp.
net/vipps/consumer/listall.asp (last visited Oct. 28, 2004).
149. See 21 U.S.C. § 381(d)(1) (2000).
150. Id.
151. See Letter from William K. Hubbard, Associate Commissioner for Policy Planning, FDA,
to Robert P. Lombardi, The Kullman Firm (Feb. 12, 2003), http://www.fda.gov/ora/import/kull-
man.pdf [hereinafter Hubbard Letter] (describing various laws violated by the reimportation of
prescription drugs).
152. For a more specific discussion of personal importation provisions, see infra notes 174-185
and accompanying text. See generally Peter S. Reichertz & Melinda S. Friend, Hiding Behind
Agency Discretion: The Food and Drug Administration's Personal Use Drug Importation Policy,
9 CORNELL J.L. & PUs. POL'Y 493 (2000). See also 21 U.S.C. § 856(a) (2000).
153. 21 U.S.C. § 381(d)(1) (2000).
154. Id.
155. Welch, supra note 1 (stating that "[w]hile acknowledging they cannot stop the importa-
tion of cheaper drugs, the FDA and Justice Department have begun efforts to crack down on
cross-border drug sales and an Oklahoma-based chain of storefront sellers" (referring to Rx
Depot)).
2005] CANADIAN PHARMACIES
they are enforcing this law.a56 The FDA has begun to issue warning
letters to parties violating this act.15 7 For example, on September 16,
2003, the FDA sent a warning letter to the Detroit-based Canadian
pharmacy, CanaRx.158 Employees of CanaRx, a United States-based
company, fill the prescriptions in Canada, bring the drugs into the
United States, and then mail the prescriptions to its U.S. customers.'
5 9
In this letter, the FDA explained that the agency learned about
CanaRx's drug reimportation activities and advised the company that
these activities are illegal.1 60 Specifically, the FDA highlighted its con-
cerns about violations of the FFDCA and other federal laws,
CanaRx's misleading statements, and public health and safety. 161 Fi-
nally, the FDA gave CanaRx fifteen days to notify the agency as to
what steps it would take to comply with the law.162
Violations of the FFDCA can result in either civil or criminal liabil-
ity.163 Under 21 U.S.C. § 332, a court can enjoin violations of the
FFDCA.164 Alternatively, a person may be held criminally liable
156. Id. Welch quotes the FDA Commissioner as saying, "We are enforcing the law, FDA's
job is to assure drug safety in the United States, and unapproved, imported drugs are illegal
because FDA does not have the resources under current law to assure their safety." Id. (internal
quotation marks omitted).
157. There are several recent instances where the FDA has issued a warning letter to a party
who violated the law regarding drug reimportation. See, e.g., Letter from David J. Horowitz,
Director, Office of Compliance, Center for Drug Evaluation and Research, FDA, to Harry Lee
Jones, Store Manager, Rx Depot, Inc. in Lowell, Arkansas (Mar. 21, 2003), http://www.fda.gov/
foi/warning.letters/g3888d.pdf; Letter from William K. Hubbard, Associate Commissioner for
Policy and Planning, FDA, to Gregory Gonot, Deputy Attorney General, State of California
(Aug. 25, 2003), http://www.fda.gov/opacom/gonot.pdf.
158. See generally Letter from David J. Horowitz, Director, Office of Compliance, Center for
Drug Evaluation and Research, FDA, to G. Anthony Howard, President, CanaRx Services, Inc.
(Sept. 16, 2003), http://www.fda.gov/foi/warning-letters/g4291d.pdf [hereinafter FDA Warning
Letter to CanaRx] (warning that the company's drug reimportation activities violate the
FFDCA).
159. Id. at 1. Specifically, the FDA letter alleged that CanaRx is
an Internet and U.S. mail operation that sends U.S. prescriptions, credit card informa-
tion, and paperwork . . . to a U.S. mail Post Office box in Detroit, MI .... [T]he pre-
scription and forms are retrieved by fax or from your Detroit P.O. Box and transported
into Canada by yourself or by one of your employees. A prescription is then obtained
from a medical doctor in Canada, and Canadian drugs are dispensed by Eastown Phar-
macy, located in the Canadian province of Ontario, to your firm for mailing directly to
the U.S. consumer.
Id. See also CanaRx, Welcome, at http://www.canarx.com/ (last visited Oct. 26, 2004).
160. FDA Warning Letter to CanaRx, supra note 158, at 1.
161. See id. at 1-4.
162. Id. at 4.
163. Hubbard Letter, supra note 151, at 1.
164. 21 U.S.C § 332 provides:
Injunction proceedings
560 DEPAUL LAW REVIEW [Vol. 54:543
under 21 U.S.C. § 333.165 The U.S. Department of Justice (DOJ) is
the primary enforcement mechanism for federal laws. 166 When a vio-
lation of the FFDCA occurs, the DOJ will bring the lawsuit.1 67
2. Other Illegalities of Reimportation
Although 21 U.S.C. § 381(d)(1) is the primary provision making
reimportation illegal, this activity will likely violate other laws. 168 For
example, certain drugs reimported from Canada might not be ap-
proved by the FDA for U.S. consumers, might not meet FDA man-
dated labeling requirements, or might not be dispensed with a valid
prescription.' 69 The FFDCA requires that all drugs introduced into
interstate commerce be FDA-approved. 170 All prescription (and
over-the-counter) drugs must also meet FDA labeling requirements,
as set forth in the FFDCA.171 Furthermore, the FFDCA requires that
all prescription drugs be dispensed with a valid prescription. 172 Addi-
tionally, all drugs must meet FDA standards as to location of manu-
facture, formulation, source and specification of active ingredients,
processing methods, manufacturing controls, container or closure sys-
tem, and appearance. 173
3. Personal Use
Canadian pharmacies mislead American consumers regarding the
legality of reimportation by claiming that a personal use exemption
(a) Jurisdiction of courts. The district courts of the United States and the United States
courts of the Territories shall have jurisdiction, for cause shown to restrain violations of
section 301 [21 USCS § 331], except paragraphs (h), (i), and (j).
(b) Violation of injunction. In case of violation of an injunction or restraining order
issued under this section, which also constitutes a violation of this Act, trial shall be by
the court, or, upon demand of the accused, by a jury.
21 U.S.C. § 332 (2000).
165. 21 U.S.C. § 333 details civil and criminal penalties available to punish a party who vio-
lates the Federal Food, Drug, and Cosmetic Act (FFDCA). Id. § 333.
166. Rothstein, supra note 38, at 351.
167. See id.
168. Hubbard Letter, supra note 151, at 2-3.
169. Id.
170. 21 U.S.C. § 355 (2000). This section provides: "No person shall introduce or deliver for
introduction into interstate commerce any new drug, unless an approval of an application filed
pursuant to subsection (b) or (j) is effective with respect to such drug." Id.
171. Id. § 353(b)(2) (listing labeling requirements). See also 21 C.F.R. §§ 201.56, 201.57 &
201.100(d) (providing the labeling requirements for prescription drugs for human use).
172. 21 U.S.C § 353(b)(1) (requiring prescription by a physician).
173. 21 C.F.R. § 314.50 (2004) (prescribing content and format required for an application to
the FDA for approval to market a new drug).
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exists.174 There are generally two types of personal use exemptions
regarding reimportation of drugs: (1) a personal import exemption for
controlled substances;1 75 and (2) a personal importation policy in the
FDA's Regulatory Procedures Manual.1 76 This discussion of personal
importation policies will, however, demonstrate that there is no per-
sonal use exception that allows the reimportation of prescription
drugs in the manner carried out by Canadian pharmacies.
First, 21 U.S.C. § 956(a), which amends the Controlled Substances
Act, allows a U.S. resident to import up to fifty dosage units of a con-
trolled medication without a prescription. 77 When crossing the bor-
der with such a substance, the substance must be declared to Customs,
the individual must intend to use the substance personally, and the
substance must not present unreasonable health risks. 178  This provi-
sion, however, applies to illegal drugs-not the prescription drugs sold
by the Canadian pharmacies.' 79
Secondly, there is a personal use exemption that applies to unap-
proved drug products imported into the United States for personal use
by individuals.180 This exemption applies to pharmaceuticals that will
become prescription drugs but have not yet obtained FDA ap-
proval. 181 This policy exists only in the FDA's Regulatory Procedures
Manual and not in any statute or regulation. 8 2 The unapproved drug
product exemption is implemented primarily by individual FDA per-
sonnel, exercising their discretion to allow the importation of small
174. For example, Canadian Pharmacy Discounts disclaims on its website, "[n]ote that U.S.
residents are limited legally to importing no more than a three months supply of prescription
drugs from a Canadian Pharmacy for personal use. Anything beyond that is not considered per-
sonal use." Canadian Pharmacy Discounts Website, at http://www.canadian-pharmacy-discounts.
com/ (last visited Oct. 26, 2004). This website serves as an informational site, linking consumers
to the Canadian pharmacy DiscountMedsForLess.com. Id.
175. 21 U.S.C. § 956(a) (2000).
176. FDA, REGULATORY PROCEDURES MANUAL: CHAPTER 9, SUBCHAPTER: COVERAGE OF
PERSONAL IMPORTATIONS, http://www.fda.gov/ora/compliance-ref/rpmnew2/ch9pers.html (last
visited Oct. 26, 2004) [hereinafter FDA REGULATORY PROCEDURES MANUAL]. Chapter 9 of the
Regulatory Procedures Manual is currently being revised by the FDA. FDA, Regulatory Proce-
dures Manual Chapter Descriptions, at http://www.fda.gov/ora/compliance-ref/rpm/default.htm
(last visited Oct. 26, 2004).
177. 21 U.S.C. § 956(a) (2000). See also U.S. Customs & Border Protection, FDA Enforce-
ment Policy Regarding the Personal Importation of Violative Drugs, at http://www.cbp.gov/xp/
cgov/travel/alerts/medication drugs.xml (last visited Oct. 25, 2004) (stating that an individual
may be allowed to import a "three month supply of an unapproved drug").
178. U.S. Customs & Border Protection, supra note 177.
179. 21 U.S.C. § 956(a) applies to all controlled substances except for subchapter I controlled
substances. 21 U.S.C. § 956(a) (2000). See id. § 812 (defining and listing controlled substances).
180. Reichertz & Friend, supra note 152, at 493-94.
181. Id. at 493-97.
182. Id. at 493-94. See FDA REGULATORY PROCEDURES MANUAL, supra note 176.
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quantities of unapproved drugs on a case-by-case basis.' 8 3 This partic-
ular personal use exemption was used in the past to allow "AIDS buy-
ers clubs" to bring unapproved AIDS therapies from Canada into the
United States. 8 4  Although the FDA acknowledges this policy, the
FDA has explained:
this policy is not intended to allow importation of foreign versions
of drugs that are approved in the U.S., particularly when the foreign
versions of such drugs are being "commercialized" to U.S. citizens.
(Foreign versions are often what Canadian pharmacies offer to sell
to U.S. consumers.) Moreover, the policy simply describes the
agency's enforcement priorities. It does not change the law, and it
does not give a license to persons to import or export illegal drugs
into the United States. Although we must concede that FDA has
not often prosecuted those importing illegal drugs into the United
States from Canada, FDA reserves the right to do so in the appro-
priate circumstance.18 5
E. The Rx Depot Case: Reimportation Law Applied
While tensions rise over the controversial Canadian pharmacies, the
FDA and DOJ have started to crack down on the reimportation of
prescription drugs from Canadian pharmacies. 186 The first targets of
the FDA were Rx Depot and Rx of Canada, LLC (Rx Canada). 18 7
On September 11, 2003, the DOJ filed a suit against Rx Depot and Rx
Canada, seeking a preliminary injunction to enforce the FFDCA.188
On November 6, 2003, Judge Claire Eagan in the United States Dis-
trict Court for the Northern District of Oklahoma issued a prelimi-
nary injunction, which effectively shut down the storefront-type
Canadian pharmacy, Rx Depot. 89
183. Reichertz & Friend, supra note 152, at 494.
184. Id.
185. Hubbard Letter, supra note 151, at 4.
186. Welch, supra note 1.
187. FDA Blitzes Reimporters In Three-Pronged Assault, DRUG INDUSTRY DAILY, Nov. 10,
2003, § 220, LEXIS, News [hereinafter FDA Blitzes Reimporters]. It seems that the FDA's next
target is CanaRx, another Canadian pharmacy. Id. The FDA has issued a warning letter to
CanaRx, stating that it is considering enforcement options against the company. Id.
188. United States v. Rx Depot, Inc., 290 F. Supp. 2d 1238 (N.D. Okla. 2003). The Arkansas
State Board of Pharmacy and the FDA together initiated the action against Rx Depot. NABP
POSITION PAPER, supra note 130, at 10. The Arkansas State Board of Pharmacy issued a "Cease
and Desist Letter" to Rx Depot, while the FDA issued a warning letter to Rx Depot. Id. Ac-
cording to the NABP, at least six state boards of pharmacy have taken action against local busi-
ness facilitating American consumers obtaining prescription drugs from Canada, including
Pennsylvania, South Dakota, Washington, Montana, and Arkansas. Id.
189. Rx Depot, 290 F. Supp. 2d at 1250.
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The defendants in the lawsuit were Rx Depot, Rx Canada, Carl
Moore, and David Peoples. 190 Rx Depot was a Nevada corporation
that conducted business in Tulsa, Oklahoma. t 9t The president of Rx
Depot was defendant Carl Moore 192 and the secretary of Rx Depot
was David Peoples.1 93 Rx Canada was a limited liability company
owned by defendant Jo-Max Moore, Carl Moore's son.
194
Rx Depot and Rx Canada were American storefronts that assisted
individuals in obtaining prescription drugs from pharmacies in Ca-
nada. 195 Rx Depot and Rx Canada had several U.S. storefront loca-
tions that would submit a U.S. customer's prescription and forms
(including a medical history form and the customer's check or credit
card information) to a cooperating pharmacy in Canada. 196 A Cana-
dian doctor then rewrote the prescription, and the prescription was
filled and shipped directly to the American customer. 197 The defen-
dant companies received about 10% to 12% commission on each sale
they facilitated for the Canadian pharmacy, thus the defendants essen-
tially acted as commissioned sales representatives for the cooperating
pharmacies.' 98
After the FDA made two undercover purchases of prescription
drugs through Rx Depot, 199 the FDA issued a warning letter to the
company.200 The letter from the FDA to Rx Depot informed defend-
ants that they were violating 21 U.S.C. § 381(d)(1), which makes
reimportation of prescription drugs illegal, and 21 U.S.C. § 355, which
190. id. at 1240.
191. Id.
192. "Moore started Rx Depot a year ago after his ex-wife was diagnosed with cancer and
discovered that the medication she needed was cheaper in Canada." Appleby, supra note 128.
193. Rx Depot, 290 F. Supp. 2d at 1240.
194. Id.
195. Id.
196. Id. Prior to being shut down, Rx Depot had 85 stores in 26 states. Appleby, supra note
128.
197. Rx Depot, 290 F. Supp. 2d at 1241.
198. Id.
199. In its first undercover purchase, an FDA investigator prepared a prescription for 60 pills
of the FDA-approved drug, Serzone, used to treat depression. Id. at 1242. The investigator
ordered a 100-pill package rather than the 60 pills "prescribed." Id. The investigator received a
package containing 99 pills (but marked that it contained 100) of a foreign-manufactured version
of the drug, known as APO-Nefazodone, from Pharmacy North, Inc., in Manitoba, Canada. Id.
at 1242-43. APO-Nefazodone is not FDA-approved, thus, importing it violated 21 U.S.C. § 355.
Rx Depot, 290 F. Supp. 2d at 1243. The drug also failed to meet U.S. labeling requirements and
had a less descriptive package insert than the FDA-approved insert for Serzone. Id. at 1243.
The second undercover purchase was of the drug Sporanox, an FDA-approved prescription
drug, manufactured in Puerto Rico for the treatment of fungal nail infections. Id. This second
prescription was also received from Pharmacy North, Inc. Id.
200. Id. at 1244.
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pertains to importing unapproved new drugs into the United States. 20 1
After correspondence between defendants and the FDA, the FDA
brought suit.20 2
At trial, the defendants (Rx Depot) unsuccessfully raised a variety
of arguments ranging from constitutional arguments to policy argu-
ments.20 3 Rx Depot argued that its business helped further the impor-
tant cause of providing cheaper prescription drugs to Americans who
could not afford prescription drugs at U.S. prices.204 Additionally, Rx
Depot offered a "geographical discrimination argument" that the gov-
ernment was applying the law unevenly because residents in border
states had more access to cheaper drugs than residents inland.20 5 Rx
Depot further argued that the government's enforcement activities vi-
olated the Privileges and Immunities Clause of the Fourteenth
Amendment and the First Amendment.20 6
Judge Eagan rejected each of Rx Depot's arguments, ruling that de-
fendants violated 21 U.S.C. § 331(d), § 331(t), and § 381(d)(1), by
reimporting prescription drugs from Canadian pharmacies. 20 7 She
also granted a preliminary injunction against the defendants, requiring
them to cease all of Rx Depot's and Rx Canada's activities, including
selling, importing, advertising, or promoting the business through any
media, including their websites. 20 8
Judge Eagan reasoned that the preliminary injunction was proper
because the test for granting a preliminary injunction was clearly
met. 20 9 In her analysis, Judge Eagan explained that the "defendants
openly and notoriously violate the law" 210 and that "the evidence con-
clusively demonstrates that the defendants' violations will continue
201. Id.
202. Rx Depot, 290 F. Supp. 2d at 1244. Defendant's response to the FDA's warning letter
was that all drugs they reimported were manufactured in the United States and that the drugs
obtained by its customers "are not FDA approved." Id. at 1294 (internal quotation marks omit-
ted). The FDA deemed this response inadequate and so notified Rx Depot through a subse-
quent letter. Id. Defendant Moore also testified that they "would continue their activities unless
this Court enjoins them." Id. In furtherance of their cause, defendants also opened up an
additional 50 Rx Depot and Rx Canada stores after they received the warning letter. Id.
203. Id. at 1238.
204. Rx Depot, 290 F. Supp. 2d at 1248.
205. Id. at 1240.
206. Id. at 1248-49.
207. Id. at 1248-50.
208. Id. at 1250-52.
209. Id. at 1247-48. An injunction is proper where the moving party shows: "1) a substantial
likelihood of success on the merits; 2) irreparable injury if the injunction is not granted; 3) that
injury outweighs any harm the injunction will cause the opposing party; and 4) the injunction is
not adverse to the public interest." Rx Depot, 290 F. Supp. 2d at 1246.
210. Id. at 1247.
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absent an injunction by this Court. ' 211 The court also emphasized,
"[niot only is Congress the best forum to address the high cost of pre-
scription drugs for U.S. citizens, but also Congress is currently consid-
ering legislation which could allow prescription drug importation from
Canada." 212
III. ANALYSIS
Great tension exists between American consumers and state gov-
ernments who want to allow the reimportation of prescription drugs
and the FDA and pharmaceutical companies who want it to remain
illegal. 213 This section will address the tensions surrounding the Cana-
dian pharmacies controversy and will discuss each group's concerns.
Then, this section will review congressional action involving
reimportation. Finally, this section will propose federal legislation
that would resolve the Canadian pharmacies debate.
A. Tensions Rising over Canadian Pharmacies
Canadian pharmacies are drawing increasing national attention.
214
Everywhere one looks, there is an article about senior citizens board-
ing buses to Canada or a news story about people not able to afford
prescription drugs. 215 The primary stakeholders include American
consumers, the FDA and NABP, pharmaceutical companies, the U.S.
government, state governments, and Canadians. This section will dis-
cuss each group's stance on Canadian pharmacies and their concerns
in making reimportation of prescription drugs legal.
1. American Consumers' Concerns Regarding Reimportation
American consumers have two main interests related to Canadian
pharmacies: (1) saving money on prescription drugs;216 and (2) the
safety and effectiveness of the drugs they obtain from Canadian phar-
macies. 217 The statistics, however, indicate that, as the "industry" of
211. Id.
212. Id. at 1245.
213. See Welch, supra note 1.
214. Gilbert M. Gaul & Mary Pat Flaherty, Canada Is a Discount Pharmacy for Americans:
FDA Doing Little to Stop Cross-Border Trade in Drugs, WASH. POST, Oct. 23, 2003, at A17.
215. See, e.g., Deaver & Swartz, supra note 5; Jones, supra note 19; Welch, supra note 1.
216. See Jones, supra note 19 (discussing how senior citizens save up to 70% on their p-e-
scription drugs when they purchase them from Canada).
217. McClellan, the former FDA Commissioner, explained: "FDA's job is to assure drug
safety in the United States, and unapproved, imported drugs are illegal because FDA does not
have the resources under current law to assure their safety." Welch, supra note 1 (emphasis
added) (internal quotation marks omitted).
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reimporting prescription drugs grows, Americans are more concerned
with saving money on prescription drugs than with the safety of
them. 21 8 The estimated one million Americans who are obtaining pre-
scription drugs from Canada are "buying under buyer-beware condi-
tions," according to Mark McClellan, the former FDA
Commissioner. 219
Evidence also suggests that while most Americans seem to favor
allowing reimportation, 220 Americans are not informed enough to
make an objective decision about the issue. 221 For example, a survey
of American consumers shows that those who were in favor of legaliz-
ing reimportation often changed their minds when given more infor-
mation about the practice. 222 Prior to receiving information (from
FDA and consumer groups) on the consequences and dangers of
reimportation, 67% of adults surveyed said they favored importing
drugs from Canada. 223  Prior to receiving information about
reimportation, 58% of those surveyed also said they would encourage
a friend or close family member to purchase prescription drugs from
Canada. 224 The consumers' answers to survey questions after review-
ing information from the FDA and consumer groups changed dramat-
ically.225 After receiving such information, 58% said they opposed
drug importation, 226 and 64% would discourage family and close
friends from reimporting. 227 Furthermore, 77% of those surveyed
said that people should not reimport drugs from Canada if it is ille-
218. See generally Carol Ukens, Uh-Oh Canada' U.S. Regulators Target the New Gold Rush-
prescription Drug Imports from Across the Border, DRUG Topics, May 5, 2003, at 37, 37. In
2002, about five Canadian pharmacies sold primarily to Americans. Id. In 2003, there were 75.
Id. The FDA Director of Pharmacy Affairs, Thomas McGinnis, expected that number to rise to
95 by July or August of 2003. Id. Furthermore, "[f]rom just a few million dollars in 2000, the
importation of price-controlled drugs from Canada has grown to a projected $800-million this
year and shows no signs of letting up." Welch, supra note 1.
219. Welch, supra note 1.
220. Survey results reveal that, generally, Americans strongly support reimportation. See
Public Opinion Strongly Behind Reimportation, Survey Says, WASH. DRUG LErER, Oct. 20,
2003, 2003 WL 10134921. A Harris Interactive Health-Care Poll released in October 2003 indi-
cated that "more than three-quarters of consumers in the U.S. said it would be 'unreasonable'
for drugmakers to try to stop Canadian pharmacies from selling drugs over the internet." Id.
Additionally, the number of survey participants who bought drugs from a Canadian or other
foreign pharmacy rose from 5% to 7% between November 2002 and October 2003. Id.
221. Ukens, supra note 218, at 47.
222. Id. (providing the results of a survey of 1,005 adults conducted for the National Associa-
tion of Chain Drug Stores Foundation in March 2003).
223. Id.
224. Id.
225. Id.
226. Id.
227. Ukens, supra note 218, at 47.
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gal,228 and 81% were more opposed to the practice after learning that
reimportation is enabling "large-scale" counterfeit drug
operations. 2
2 9
2. The FDA's and the NABP's Concerns Regarding Reimportation
The FDA and NABP 230 are opposed to legalizing the reimportation
of prescription drugs from Canada. 23' The FDA cites public health
concerns as its primary reason for opposing the reimportation of pre-
scription drugs.232 Specifically, the FDA argues that drugs obtained
from Canadian pharmacies are of "unknown quality," even though
they appear to be or purport to be the same FDA-approved products
available in the United States.2 33 The FDA further argues that Cana-
dian pharmacies may provide "expired, subpotent, contaminated or
counterfeit product, the wrong or a contraindicated product, an incor-
rect dose, or drugs unaccompanied by adequate directions for use."
234
While recognizing that the increasing cost of prescription drugs is an
important public health issue, the FDA urges Congress to remedy the
problem by implementing a prescription drug benefit in Medicare.
2 35
In furtherance of its views on reimportation and in the name of
public health, the FDA has unleashed a three-prong attack on
reimportation. 236 First, the FDA began the process of shutting down
Rx Depot, a Canadian pharmacy with storefronts across the United
States.237 Second, the FDA has begun targeting another Canadian
228. Id.
229. Id.
230. NABP is the professional association made up of the State Boards of Pharmacy for all
states in the United States, as well as the Boards of Pharmacy of "the District of Columbia,
Guam, Puerto Rico, the Virgin Islands, New Zealand, eight Canadian provinces, two Australian
states, and South Africa." NABP Website, at http://www.nabp.net (last visited Oct. 28, 2004).
231. NABP POsITIoN PAPER, supra note 130, at 12 (explaining that the NABP opposes the
legalization of drug reimportation); Letter from Mark McClellan, Commissioner of Food and
Drugs to The Honorable W.J. "Billy" Tauzin, Chairman, House Committee on Energy and
Commerce 1 (July 18, 2003), http://www.phrma.org/publications/quickfacts/2003-07-2 5 .8 13 .pdf
[hereinafter FDA Letter to House] (explaining that FDA opposes the legalization of drug
reimportation). See also Examining Prescription Drug Reimportation: A Review of a Proposal to
Allow Third Parties to Reimport Prescription Drugs: Hearing Before the Subcomm. on Health of
the House Comm. on Energy and Commerce, 107th Cong. 32 (2002) (statement of William Hub-
bard) [hereinafter Prescription Drug Reimportation].
232. FDA Letter to House, supra note 231, at 1.
233. Id. at 2-3.
234. Id. at 2. Prescription drugs obtained from Canada also may not have adequate labeling
or package inserts, and there is no way to know whether the drugs have been stored in proper
conditions to avoid a loss of efficacy. Id.
235. Id. at 4.
236. FDA Blitzes Reimporters, supra note 187.
237. Id. See also supra notes 186-212 and accompanying text.
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pharmacy, CanaRx.2 38 Early in November 2003, the FDA issued a
warning letter to CanaRx, saying that the agency was considering its
enforcement options against the company because it is violating fed-
eral laws, similar to Rx Depot's violations. 239 Finally, the FDA Com-
missioner of Policy and Planning, William H. Hubbard, "blasted a
widely circulated study" commissioned by Illinois Governor Rod
Blagojevich regarding how much money the State of Illinois would
save by reimporting prescription drugs.2 40 Hubbard criticized the
study as overestimating the savings that Illinois would receive, empha-
sized that large-scale reimportation would encourage drug counter-
feiting, and explained that "there are far better ways to get savings in
medical costs for Illinois residents. '241
Like the FDA, the NABP also opposes reimporting prescription
drugs from Canada. 242 The NABP has urged the FDA to enforce the
current laws regarding the reimportation of drugs from foreign coun-
tries.243 In a letter from the NABP to Tommy G. Thompson, former
HHS Secretary, and Mark B. McClellan, former FDA Commissioner,
the NABP explained:
While recognizing that access to affordable medications is an impor-
tant concern for U.S. citizens, NABP believes that existing laws and
regulations prohibiting this activity need to be obeyed and enforced
to allow for the safe and regulated supply of drugs and medications.
Allowing the practice of cross-border Internet trade of medicines to
continue and expand opens up the U.S. population to those who
would take full advantage of the lack of regulatory enforcement to
increasingly prey on American patients. 244
The NABP has also criticized the "blatant disregard for the law by
those in positions of authority," such as politicians sponsoring bus
trips to Canada and Mexico. 245 The NABP explains that when author-
ity figures support illegal activities, it sends a confusing message to
Americans and wrongfully de-emphasizes the public health risks at
stake.246 In addition to supporting the FDA's position on reimporta-
238. FDA Blitzes Reimporters, supra note 187. CanaRx is the only drug reimporter in Spring-
field, Massachusetts, which is the only U.S. jurisdiction actively reimporting drugs for its re-
sidents. Id.
239. Id.
240. Id.
241. Id. (internal quotation marks omitted).
242. See NABP POSITION PAPER, supra note 130, at 1.
243. Id. at 9.
244. Id. (quoting Letter from Carmen A. Catizone, Executive Director/Secretary NABP to
Tommy G. Thompson, Secretary, United States Department of Health and Human Services and
Mark B. McClellan, Commissioner, FDA (Feb. 26, 2003) (on file at NABP)).
245. Id. at 12.
246. See id.
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tion, the NABP emphasizes that what is particularly disturbing about
Canadian pharmacies is that "patients may never know there is a
problem" with the drugs they are obtaining from those pharmacies.
247
If patients discover a problem, they have little or no recourse because
the actual dispenser of the drug may be unknown, there may be no
legal authority having jurisdiction over the problem, and oftentimes
patients waive their right to sue when dealing with Canadian
pharmacies. 24
8
3. Pharmaceutical Companies' and the Pharmaceutical Research
and Manufacturers of America's (PhRMA) Concerns
Regarding Reimportation
The pharmaceutical companies and Pharmaceutical Research and
Manufacturers of America (PhRMA)2 49 oppose the practice of Amer-
icans reimporting prescription drugs from Canada.250 Pharmaceutical
companies and PhRMA support a Medicare prescription drug benefit
and pharmaceutical company programs rather than reimportation.
251
PhRMA's website also contains a statement directed to individuals
unable to afford their medicines: "[f]or patients who can't afford
medicines, we urge you to avoid the risks of unsafe imports."
252
PhRMA then encourages the individuals to visit a website containing
"information about pharmaceutical-company programs offering free
and discounted medicines to" those who qualify.
253
Some pharmaceutical companies have begun to take direct action to
secure their current market and pricing schemes by means of restrict-
ing supply and raising prices of pharmaceuticals. 254 Five major drug
companies have moved to restrict supplies of pharmaceuticals to Ca-
247. Id. at 1.
248. See NABP PosrrloN PAPER, supra note 130, at 1.
249. PhRMA is the primary lobbying group representing America's "leading research-based
pharmaceutical and biotechnology companies, which are devoted" to developing beneficial
medicines. PhRMA, Who We Are, at http://www.phrma.org/whoweare/ (last visited Jan. 26,
2005).
250. See PhRMA, Imports Carry Risks, at http://www.phrma.org/publications/publications/
20.08.2003.832.cfm (last visited Oct. 28, 2004).
251. Id.
252. Id.
253. Id. The website consists of information linking users to member pharmaceutical compa-
nies that offer programs for those who are eligible to receive free or discounted medications. See
Helping Patients Website, at https://www.helpingpatients.org/Intro.php (last visited Oct. 28,
2004).
254. Eli Lilly Fights Drug Sales from Canada, BIOTECH WEEK, Nov. 12,2003, at 154, Westlaw,
NEWSRX Database; Bernard Simon, Curtailing Medicines from Canada, N.Y. TIMEs, Nov. 11,
2003, at W1.
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nadian pharmacies. 255 As of October 21, 2003, Eli Lilly joined Pfizer
Inc. (Pfizer), GlaxoSmithKline (GSK), AstraZeneca, and Wyeth in
limiting sales of their drugs to the amount sufficient to supply the Ca-
nadian market only.256 Using loopholes in the Canadian price control
system, several pharmaceutical companies have also raised the prices
4% to 8% since the summer of 2003.257 An executive at Shoppers
Drug Mart, one of Canada's largest drugstore chains, said "there was
little doubt that the recent price increases were an attempt by drug
makers to narrow the gap between [drug prices in] Canada and the
United States. '2 58 Because the movement to restrict supply and raise
prices began in 2003, it may be too early to tell what effect the re-
stricted supply of drugs and increased prices will have on the Cana-
dian pharmacy industry.259 One Canadian pharmacy has already
devoted a portion of its website to fighting GSK's ban.260
The pharmaceutical industry and PhRMA cite "well-documented
concerns about the safety of imported drugs" as the basis of their op-
position to reimportation.261 Despite this, it is extremely hard to be-
lieve that they are not also concerned about their own profits.
PhRMA touts the Medicare prescription drug benefit, but adding a
prescription drug benefit will not impact the pricing of pharmaceuti-
cals. 262 Supporting the Medicare prescription drug benefit, which
does not lower the prices of drugs, allows PhRMA to show concern
255. Eli Lilly Fights Drugs Sales from Canada, supra note 254, at 154.
256. Id.
257. Simon, supra note 254.
258. Id.
259. "The effectiveness of efforts by the brand-name companies to choke off supplies to the
online pharmacies is hard to judge. IMS Health, a market research group in Montreal, estimated
the growth in wholesale shipments of prescription drugs to Canadian pharmacies slowed to 5
percent in the third quarter." Id. The owner of one online Canadian pharmacy has been quoted
as saying "that the clampdown by the pharmaceutical groups has changed the amount of effort it
takes to purchase supplies every day. What used to take 15 minutes now takes two or three
hours." Id. (internal quotation marks omitted).
260. See Canadian Drugs CA Website, at http://canadiandrugs.ca/ (last visited Oct. 28, 2004).
The Canadian pharmacy Canadian Drugs CA is urging it customers to help ensure that they can
continue to supply Canadian drugs to Americans. Id. The website encourages customers to
voice their opposition to GlaxoSmithKline's (GSK) restriction on Canadian supply by voicing
their concerns to U.S. Senators, the GSK company, and the Canadian Competition Bureau. Id.
261. PhRMA, The Issues, at http://www.phrma.org/issues/reimportation/ (last visited Oct. 28,
2004) (explaining PhRMA's position against legalizing reimportation but favoring a Medicare
prescription drug benefit).
262. See Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L.
No. 108-173, 117 Stat. 2066.
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about the problem of high costs of prescription drugs without reduc-
ing the companies' bottom lines.
263
4. U.S. Government's Concerns Regarding Reimportation
Currently, the reimportation issue is also a hot topic in Congress.
2 64
President George W. Bush's administration has issued a Statement of
Administration Policy explaining that the administration strongly op-
poses H.R. 2427, the bill currently in Congress that would legalize
reimportation from Canada.265 Instead, President Bush and his sup-
porters prefer a Medicare prescription drug benefit, such as the one
recently enacted. 266 The President argues that the Medicare prescrip-
tion drug benefit would reduce the hardship of prescription drug costs
for senior citizens. 267 Of course, it should not be overlooked that
Bush and the Republican Party have received "tens of millions of dol-
lars in campaign contributions from the pharmaceutical industry. '268
On the other hand, most Democrats support legalizing reimporta-
tion.269 Democrats who criticize the pharmaceutical industry argue
that pharmaceutical companies get tax breaks for R&D and spend
"lavishly on advertising and lobbying. ' 270 They further argue there
are no reported cases of illnesses from drugs imported from Canadian
pharmacies. 27'
5. State and City Governments' Concerns Regarding Reimportation
The FDA remains steadfast in its opposition to reimportation, re-
fusing to approve any large-scale proposals to import prescription
drugs from Canada. 272 As the FDA continues to oppose reimporta-
tion, several state and city governments are getting involved in the
reimportation issue. 273 Local governments in Illinois, Wisconsin, Min-
263. See generally id.; PhRMA, The Issues, supra note 261 (explaining PhRMA's position on
the issue of reimportation).
264. Welch, supra note 1.
265. EXECUTIVE OFFICE OF THE PRESIDENT, STATEMENT OF ADMINISTRATION POLICY, H.R.
2427 - PHARMACEUTICAL MARKET ACCESS ACT OF 2003 (July 23, 2003), available at http://www.
phrma.org/publications/quickfacts/200
3
-
0 7
-
2 5
.
8 14 .pdf [hereinafter STATEMENT OF ADMINISTRA-
TION POLICY].
266. Id.
267. Id.
268. Welch, supra note 1.
269. See id.
270. Id.
271. Id.
272. Ceci Connolly, Kennedy Endorses Drug Importation; Senator Criticizes FDA, Plans Bill
for Limited Program, WASH. POST, Dec. 19, 2003, at A16.
273. First U.S. State Is Set to Buy Canadian Drugs; Cross-Border Sales of Drugs, PHARMA
MARKETLETrER, Dec. 15, 2003, 2003 WL 55674850 [hereinafter First U.S. State]; Health Canada
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nesota, Massachusetts, New Hampshire, and New York have all taken
steps toward facilitating reimportation. 274
City and state governments' efforts toward legalizing reimportation
fall into three distinct categories. First, local government efforts to-
wards legalizing generally consist of plans to establish programs to
provide city employees and retirees with drugs from Canadian phar-
macies. 275 Secondly, Illinois Governor Rod Blagojevich is attempting
to obtain federal approval to have an Illinois reimportation program
designated as the nation's first reimportation pilot program.2 76 Fi-
nally, officials in Wisconsin and Minnesota are initiating investigations
into whether pharmaceutical companies are violating antitrust laws by
restricting sales to Canadian companies that export prescription drugs
to the United States. 277
To date, several cities and one state have announced plans to
purchase for their residents prescription drugs from Canada. 278 New
Hampshire is the only state so far to unveil plans to obtain drugs from
Canadian pharmacies for prisoners, Medicaid recipients, and retired
state employees. 279 The largest U.S. city to reveal such a plan is Bos-
ton, which plans to offer drugs from Canadian pharmacies as an op-
tion for city employees and retirees. 280 Additionally, Springfield,
Massachusetts was the first jurisdiction to actually begin importing
prescription drugs from Canada for its employees.2 81 Burlington, Ver-
Concerned Reimportation Will Cause Shortages, DRUG INDUSTRY DAILY, Oct. 31. 2003. § 214.
LEXIS, News [hereinafter Health Canada Concerned].
274. Health Canada Concerned, supra note 273. Other states such as Iowa, Minnesota, and
California have "expressed interest." Id.
275. One Washington Post staff writer noted that "the FDA's adamancy has served to em-
bolden the growing number of elected officials across the country who say they are desperate for
a way to reduce skyrocketing drug bills and score political points with consumers." Connolly,
supra note 272.
276. Monica Davey, Illinois to Seek U.S. Exemption to Buy Drugs from Canada, N.Y. TIMES,
Dec. 22, 2003, at A27.
277. Joe Manning, Doyle Seeks Antitrust Probe of Drug Firms, MILWAUKEE J. SENTINEL, Dec.
20, 2003, at 3D; States Likely to Coordinate Canadian Distribution Probes, DRUG INDUSTRY
DAILY, Nov. 14, 2003, § 224, LEXIS, News [hereinafter States Likely to Coordinate] (discussing
Minnesota).
278. First U.S. State, supra note 273.
279. Id. See also Sanjay Gupta, Blame Canada: New Hampshire Will Defy the FDA and Buy
Drugs on the Net, TIME, Dec. 22, 2003, at 130, 130. Gupta, CNN Medical Correspondent, opines
that the New Hampshire plan "sounds pretty safe to me." Id.
280. First U.S. State, supra note 273. The City of Boston spends $61 million per year on pre-
scription drugs and estimates that its plan to offer drugs from Canadian pharmacies will save the
city $1 million per year. Id.
281. Health Canada Concerned, supra note 273. Springfield, Massachusetts expects to reduce
its $18 million annual drug bill by half. Cyril T. Zaneski, Canada's Internet Pharmacies Thriving
on Business from U.S.; Low Costs of Prescriptions Attract Seniors, Criticism, BALT. SUN, Dec. 21,
2003, at 1A.
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mont has also announced its intent to import prescription drugs for
city employees. 28 2
While other government officials seem to be ignoring the law, Illi-
nois Governor Blagojevich insists that he will not break the law.28 3
Blagojevich's efforts began with an online petition to the FDA in
hopes of persuading the FDA to allow Illinois to import Canadian
drugs. 284 On December 22, 2003, Governor Blagojevich and Con-
gressman Rahm Emanuel (D) announced they were sending a formal
request to former HHS Secretary Tommy Thompson proposing that
federal authorities waive the prohibition on reimportation. 28 5 If ap-
proved, the proposal would allow Illinois to reimport prescription
drugs for its state employees and retirees. 286 Blagojevich emphasized
that he wanted to "work hand in hand with the federal government to
safely and legally import prescription drugs from Canada. '28 7 Despite
insisting he will not break the law, Governor Blagojevich was embark-
ing on a path that will inevitably require him to do so. Ironically, on
August 17, 2004, Governor Blagojevich announced his plan to provide
Illinois residents with access to prescription drugs from Canada, from
Ireland, and from the United Kingdom. 288 Then on October 5, 2004,
Governor Blagojevich unveiled I-Save Rx, a program that allows Illi-
nois, Wisconsin, and Missouri residents to obtain prescription drug re-
fills from Canadian and British pharmacies.289
282. Zaneski, supra note 281.
283. Davey, supra note 276, at A27.
284. See The Fight for Affordable Prescription Drugs, at http://www.affordabledrugs.il.gov/
petitionInfo.cfm (last visited Oct. 28, 2004).
285. Press Release, Governor Rod R. Blagojevich, Blagojevich and Emanuel Ask HHS Secre-
tary Thompson to Let Illinois Import Approved Canadian Prescription Drugs (Dec. 22, 2003), at
http://www.illinois.gov/PressReleases/ShowPressRelease.cfm?SubjectID=32&RecNum=2549
[hereinafter Blagojevich and Emanuel Ask]; Illinois Governor Pushes for Drug-Buying Program
(Dec. 22, 2003), at http://www.cnn.com/2003/HEALTH/12/22/prescription.drugs.ap [hereinafter
Illinois Governor].
286. Illinois Governor, supra note 285. The proposal has three distinct limitations: (1) that
only a preapproved list of drugs would be reimported; (2) all prescriptions would be first filled
by an Illinois pharmacist and only refills could be obtained from Canadian pharmacies; and (3)
participation in the program would be entirely voluntary. Id.
287. Blagojevich and Emanuel Ask, supra note 285.
288. Press Release, Governor Rod R. Blagojevich, Governor Blagojevich Announces Plan to
Make Illinois First State in the Nation to Provide Consumers with Access to Prescription Drugs
from Canada, Ireland and the UK (Aug. 17, 2004), http://www.illinois.gov/PressReleases/Show-
PressRelease.cfm?SubjectlD=32&RecNum=3295 (announcing his plan to provide Illinois re-
sidents with access to Canadian prescription drugs).
289. Courtney Flynn, State Starts Drug Import Plan, CHICAGO TRIB., Oct. 5, 2004, § 1, at 1.
The program is called I-SaveRX. See I-SaveRX, at www.isaverx.net (last visited Oct. 28, 2004).
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Wisconsin and Minnesota 290 are launching a different type of attack
on the issue of reimportation, investigating whether pharmaceutical
companies are violating antitrust laws by restricting sales to Canadian
pharmacies that export prescription drugs to American citizens.2 91
On December 19, 2003, Wisconsin Governor Jim Doyle asked the
United States Attorney General John Ashcroft to investigate whether
prescription drug companies have violated antitrust laws.292 In spring
2003, the Minnesota Attorney General, Mike Hatch, launched an in-
vestigation into GSK's Canadian distribution practices. 293 Hafch
claims that GSK has "violated state antitrust law and perhaps con-
spired with other drugmakers to do so.''294 In response, GSK argues
that it is immune from violating antitrust laws because it is assisting
the FDA in furthering its goal of preventing illegal reimportation of
prescription drugs.295 At the time of writing, Hatch is still involved in
the ongoing investigation of GSK's alleged "conspiracy" to prevent
reimportation of prescription drugs from Canada.296
290. Minnesota has also launched a website that provides contact information to Minnesota
residents regarding state-approved Canadian pharmacies but does not have the capability of
taking orders directly through the website. See Minnesota RxConnect, at http://www.Min-
nesotaRxConnect.com (last visited Oct. 28, 2004). Despite a warning letter from the FDA, Min-
nesota's website is still online to date. See Helkei Tinsley, Current Public Law and Policy Issues:
Prescriptions Without Borders: America Looks to Canada for Answers to Solve the Prescription
Drug Pricing Predicament in the U.S., but Is Importation Really the Solution?, 25 HAMLINE J.
PUB. L. & POL'Y 437, 468-72 (2004) (explaining in further detail the Minnesota website); Minne-
sota's Canadian Drug Website Draws FDA Warning, USA TODAY. Feb. 24. 2004. http://www.
usatoday.com/tech/webguide/internetlife/2004-02-24-fda-minn-warning-x.htm (explaining the
FDA warning letter issued to Minnesota officials regarding the website).
291. See Manning, supra note 277; States Likely to Coordinate, supra note 277.
292. Manning, supra note 277.
293. Minnesota AG Demands GSK's Documents on Canadian Drugs Sales, DRUG INDUSTRY
DAILY, Oct. 2, 2003, § 193, LEXIS, News.
294. Id.
295. Press Release, GSK, GSK's Position on the Minnesota AG's Motion to Compel Docu-
ments, http://www.gsk.com/press-archive/press2003/pressl11172003b.htm (last updated Nov. 17,
2003). GSK explains:
The FDA has specifically encouraged manufacturers' assistance in halting the illegal
importation of drugs. State antitrust enforcement that conflicts with the FFDCA and
the FDA's initiatives to halt imports of unapproved drugs from Canada is preempted
under the Supremacy Clause. Because GSK Canada's restrictions are consistent with
federal drug policy, and because illegal trade is not protected by the antitrust laws, the
AG may not pursue an antitrust enforcement action against GSK for its efforts to stem
illegal importation of its medicines. There simply cannot be a conspiracy in violation of
the antitrust laws to restrain trade in illegal goods.
Id.
296. Press Release, Minnesota Attorney General, Hatch Applauds Landmark Decision That
Prescription Drugs May Legally Be Imported from Canada (May 10, 2004), at http://www.ag.
state.mn.us/consumer/PR/PR040510GlaxoSmithKline.htm. See also Fresh Off 2003 Victories,
Pharma Lobbying Faces New Challenges, THE FOOD & DRUG LETTER, Dec. 19, 2003, No. 690,
2003 WL 10527048.
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6. Canadians' Concerns Regarding Reimportation
Americans are not the only ones engaged in political debate over
Canadian pharmacies. Canadians are also upset about American
reimportation of Canadian drugs.297 Canadians are concerned that le-
galizing reimportation will restrict Canadians' access to the newest
drugs by destroying incentives to invest in R&D to make new and
better drugs.298 In response, the Canadian National Association of
Pharmacy Regulatory Authorities (NAPRA) 299 asked the Canadian
government to enact laws prohibiting the export of Canadian drugs to
the United States.300 In a November 13, 2003 press release, NAPRA
said that exports of prescription drugs are causing difficulties in pro-
tecting Canadian public safety, placing much of the blame on the fail-
ure of the United States to enforce federal law prohibiting
reimportation.30 1 To date, the Canadian government has not enacted
such legislation.
The Canadian public is not the only concerned group; executives at
Canadian internet pharmacies also have concerns regarding
reimportation.30 2 Canadian pharmacies that export prescription drugs
to Americans "are watching with a mixture of delight and dread as
more and more cities and states announce that they are considering
reimportation programs. '30 3 Canadian pharmacies want to expand
their businesses to increase profits but have concerns regarding their
ability to handle a "massive influx of new customers." 30 4 Addition-
ally, these businesses do not want to "taunt the pharmaceutical indus-
try," which is already restricting the supply of drugs to Canadian
pharmacies, and cause them to take even more drastic measures to
reduce the supply of drugs.305
297. Pipes, supra note 113.
298. Id. "While Americans are flocking to Canada to get inexpensive drugs, Canadians have
for years been going in the opposite direction, desperately seeking new and necessary medicines
that they can only obtain in the United States." Id.
299. See NAPRA Website, at www.napra.org (last modified Oct. 28, 2004) (providing informa-
tion about the organization).
300. Canadian Pharmaceutical Agency Wants Ban on Exports to U.S., PHARMACEUTICAL &
MED. DEVICE L. BULL., Dec. 12, 2003, at 5.
301. Id. See Press Release, Canadian National Association of Pharmacy Regulatory Authori-
ties, Canadian Pharmacy Regulators Call for Government Action on Prescription Exports (Nov.
13, 2003), http://www.bcpharmacists.org/pdf/NAPRApressrelease03.pdf.
302. Reimportation: Advocates to Push for Legislation in 2004, AM. HEALTH LINE, Dec. 15,
2003, Westlaw, APN-HE Database [hereinafter Reimportation].
303. Id.
304. Id. (internal quotation marks omitted).
305. Id. (internal quotation marks omitted).
2005]
576 DEPAUL LAW REVIEW [Vol. 54:543
B. Proposed Federal Legislation on Reimportation
Although state and local governments favoring reimportation seek
to implement reimportation programs, proponents of reimportation
are calling for the passage of federal legislation.30 6 Such federal legis-
lation would amend the FFDCA to allow U.S. citizens and states to
purchase prescription drugs from Canada.30 7 One bill currently in
Congress, H.R. 2427,308 would legalize reimportation by amending the
FFDCA if passed. 30 9
On July 25, 2003, the House of Representatives passed 310 H.R.
2427, the Pharmaceutical Market Access Act of 2003. 311 H.R. 2427
would legalize reimportation by requiring the Secretary of HHS to
promulgate rules permitting "wholesalers" and "qualifying individu-
als" to reimport prescription drugs into the United States.312 H.R.
2427 would amend the Medical Equity and Drug Safety Act of 2000
(MEDSA), a previous effort to legalize reimportation. 313 The law was
passed by Congress but never enacted. 314 MEDSA provided the Sec-
retary of HHS with the option to implement the law, but the Secretary
declined to do so. 315 On the other hand, H.R. 2427 would require the
306. Id. For a comprehensive discussion of past federal legislative efforts, see Creech, supra
note 36, at 622-39. The most notable past attempt at legalizing reimportation was the Medical
Equity and Drug Safety Act of 2000 (MEDSA). See id. at 622-28. Congress passed this law,
which is codified at 21 U.S.C. § 384, but the Secretary of HHS never implemented it due to
various problems with the bill. Id. at 635. The four major problems with the bill were (1) the
bill's labeling requirements gave drug manufacturers too much control over reimportation; (2)
the bill's Sunset provision took away incentive for pharmacists and wholesalers to invest in the
resources necessary for reimportation (the Sunset provision required that the Act was only effec-
tive for five years after implementation); (3) because the bill would have allowed manufacturers
to interfere with the resale of prescription drugs, language trying to prevent such an inference
was not strong enough; and (4) the Act was not sufficiently funded. Id. at 635-39.
307. See H.R. 2427, 108th Cong. (2003).
308. The Senate companion to H.R. 2427, S. 1781, is not currently on the Senate's legislative
calendar, which "identifies bills and resolutions awaiting Senate floor actions." United States
Senate, Senate Legislative Calendar, at http://www.senate.gov/pagelayout/legislative/
one item and teasers/Senatejleg-calendarpage.htm (last visited Oct. 28, 2004). Government
aides who work for Representative Gil Gutknecht (the sponsor of the bill) and Representative
Bernard Sanders (who assisted in drafting the bill) say "they expect a 'big push' to get a bill
through Congress." Reimportation, supra note 302.
309. Id.
310. Elizabeth White, Pharmaceuticals Drug Importation Bill Clears House, As 87 Republi-
cans Buck Party Leaders, BNA's HEALTH CARE DAILY REPORT, July 28, 2003, Westlaw,
BNAHCD Database.
311. H.R. 2427.
312. Id.
313. 21 U.S.C. § 384.
314. Creech, supra note 36.
315. For a discussion of why the MEDSA was never enacted into law, see Creech, supra note
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Secretary to lift the ban on reimportation within 180 days of when it
was passed.316
If enacted into law, H.R. 2427 would require that anyone reimport-
ing a drug into the United States provide the Secretary of HHS with
records containing: "the name and amount of the active ingredient,
the date of shipment and quantity shipped, points of origin and desti-
nation, the prices paid and charged by the importer, and the manufac-
turer's lot or control number for the product. '317 H.R. 2427 would
also require reimported drugs to be in counterfeit-resistant packag-
ing318 and to comply with the sections of the FFDCA relating to ap-
proval, misbranding, and adulteration of drugs. 319
IV. IMPACT
Reducing the cost of prescription drugs without sacrificing invest-
ment on R&D and without reducing quality and safety is a difficult, if
not impossible, task. Because of the complexity of the issue and the
high tensions between groups involved, there is no easy answer. Al-
though the problem of escalating prescription drug costs is complex,
several proposals could lessen the impact of the high costs of prescrip-
tion drugs. This section will review proposed initiatives including
manufacturer discount programs, a Medicare prescription drug bene-
fit, legalizing reimportation, and price controls in the United States.
A. Manufacturer Discount Programs
Several major pharmaceutical companies, either jointly or as a
team, offer discount programs on pharmaceutical products for low-
income seniors or other eligible customers. For example, the Together
Rx program is a joint effort of major drug manufacturers that offers
eligible senior citizens discounts of up to 20% to 40% on many of
their products. 320 Together Rx was founded by Abbott Laboratories,
AstraZeneca, Aventis, Bristol Myers Squibb, GSK, Janssen, Novartis,
and Ortho-McNeil. 321 Together Rx allows a patient to carry just one
316. H.R. 2427.
317. H.R. 2427, The Pharmaceutical Market Access Act of 2003, as Passed by the U.S. House of
Representatives on July 23, 2003 (Nov. 19, 2003), at http://www.cbo.gov/showdoc.cfm?index=
4852&sequence=0 (summarizing the requirements of H.R. 2427).
318. H.R. 2427.
319. Id. (referring to §§ 501, 502, and 505 of the FFDCA).
320. Together Rx, Frequently Asked Questions, at http://www.togetherrx.com/faq.html (last
visited Oct. 28, 2004).
321. Together Rx, Founding Members, at http://www.togetherrx.com/alliance.html (last visited
Oct. 28, 2004).
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card to get discounts on prescription drugs from the member PhRMA
manufacturers. 322
Similarly, other companies such as Pfizer and Eli Lilly have their
own individual programs. Pfizer offers the "Pfizer For Living Share
Card," where eligible senior citizens can obtain certain Pfizer pre-
scription drugs for a substantially reduced rate.323 Eli Lilly offers a
similar program called Lilly Answers.324 In Eli Lilly's program, low-
income senior citizens can purchase Eli Lilly's prescription drugs at a
substantial discount. 325
While these manufacturer discount programs are a good first-step
toward reducing prescription drug prices, they are not a sufficient so-
lution. These programs are only directed toward senior citizens. Al-
though the high cost of drugs greatly affects senior citizens, all
Americans, not just senior citizens, are suffering from the staggering
prices of prescription drugs. For example, children and adults with
chronic ailments who require daily medications are overlooked by the
manufacturer discount programs. While these programs should be en-
couraged to continue until more permanent measures are effectuated,
manufacturer discount programs are only a partial solution.
B. Addition of a Prescription Drug Benefit to Medicare
Opponents of reimportation and advocates of the pharmaceutical
industry called for the legislature to add a prescription drug benefit to
Medicare rather than legalizing reimportation.3 26 The Senate voted to
pass the Prescription Drug and Medicare Improvement Act of 2003327
on November 25, 2003,328 and it was enacted into law on December 8,
2003.329 This piece of legislation was the "first major expansion of the
Medicare program since it was created thirty-eight years ago. ' 330 It
provides prescription drug coverage for low-income senior citizens
and disabled persons.331 Until 2006, when the main benefit of the leg-
islation goes into effect, drug discount cards will be available to senior
322. Together Rx, Frequently Asked Questions, supra note 320.
323. See Pfizer For Living, Who Can Enroll?, at http://www.pfizersharecard.com/nudoyou-
qual.asp?cardlmageOver=2 (last visited Oct. 28, 2004).
324. Lilly Answers, at http://www.lillyanswers.com (last visited Oct. 28, 2004).
325. See id.
326. Jill Zuckman & Bruce Japsen, Medicare Drug Bill Redraws Landscape, CHI. TRIB., Nov.
26, 2003, § 1, at 1 (discussing the views of notable members of Congress).
327. Medicare Prescription Drug, Improvement and Modernization Act of 2003, Pub. L. 108-
173, 117 Stat. 2066.
328. Zuckman & Japsen, supra note 326.
329. 117 Stat. at 2066.
330. Zuckman & Japsen, supra note 326.
331. §§ 101-102, 117 Stat. at 2071-81.
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citizens from competing companies that "charge different annual fees
and different prices for the same medications.
332
This bill has received mixed reviews. Republicans (including Presi-
dent Bush) view the bill very positively because the passage of the bill
gives Republicans an edge on what is typically a Democratic issue.
333
Pharmaceutical companies support the bill because it does not affect
their pricing systems or profits. 334 Senior citizens, the individuals the
bill was supposed to help, are "confused" or "think it stinks. ' 335
The primary objection senior citizens have is that they find the bill
complicated and difficult to understand. 336 In response, the Bush ad-
ministration, American Association of Retired Persons, and HHS are
undertaking efforts to explain the new law to senior citizens.337 Other
objections are that senior citizens and retirees who currently have pre-
scription drug coverage through an employer's insurance will be worse
off on Medicare if that employer discontinues insurance, which is an
unfortunate trend many retirees are experiencing. 338 Also, "[t]he leg-
islation has been criticized for not offering seniors, particularly mid-
dle-income seniors, much of a prescription-drug benefit."
339
Wisconsin Senator Herb Kohl (D) argued:
The bill fundamentally changes the nature of Medicare .... Instead
of enhancing the current guaranteed benefit under Medicare with
prescription drug coverage, the bill allocates billions to insurance
companies to entice them to serve Medicare beneficiaries.
And what will these insurance companies do with this extra money?
They will design their plans to attract the healthiest, wealthiest se-
niors-and leave poorer, sicker seniors in traditional Medicare fac-
ing higher costs. 340
332. Edward Walsh & Bill Brubaker, Drug Benefit's Impact Detailed; Many Will Face Big Out-
of-Pocket Costs, WASH. POST, Nov. 26, 2003, at A10.
333. See Bob Kemper, Bush, GOP Revel in Medicare, Economy, CHI. TRIB. Nov. 26, 2003, § 1,
at 11.
334. See Statement by Alan F. Holmer, President and CEO, Pharmaceutical Research and
Manufacturers of America (PhRMA), On the Passage of the Medicare Prescription Drug Benefit,
PR NEWSWIRE, Nov. 25, 2003, LEXIS, News.
335. Confusion Surrounds New Medicare Law (Dec. 22, 2003), at http://www.cnn.com/2003/
HEALTH/12/22/medicare.confusion.ap.
336. Id.
337. Id.
338. Tammie Smith, Medicare Overhaul 'Bad Deal'?; Advocates for Senior Citizens Are Pre-
pared to Get to Work to Try to Improve the Plan, RICH. TIMES DISPATCH, Nov. 26, 2003, at A-11,
2003 WL 8040168.
339. Id.
340. Patricia Simms, Kohl, Feingold Say Medicare Legislation Is Seriously Flawed, Wisc.
STATE J., Nov. 25, 2003, at Al (internal quotation marks omitted).
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Kohl further explained that the government will actually pay these
insurance companies more than it would currently cost Medicare to
provide the same coverage. 341 Likewise, some people worry that this
bill might lead to an eventual privatization of Medicare. 342
Although some have criticized the passage of a Medicare prescrip-
tion drug benefit, many view it as a step in the right direction.343 One
advocate for senior citizens has said that this "gives all of us a chance
to do some advocacy work on it, what it is and what we still need to
have. '344 Like the manufacturer discount programs, the addition of a
Medicare prescription benefit is directed specifically toward senior cit-
izens and will not benefit working-age Americans who do not qualify
as low-income persons. While senior citizens are among the most af-
fected groups, this measure also does not address the real problem-it
does not lower the high cost of pharmaceuticals nor does it cure any of
the reasons for these high costs.
C. Legalizing Reimportation Through H.R. 2427, The
Pharmaceutical Market Access Act of 2003
Legalizing reimportation is not an adequate solution to remedy the
high costs of prescription drugs. If enacted into law, H.R. 2427 would
legalize reimportation. The idea behind reimportation is to "get U.S.
prices down to Canada's prices. ' 345 The primary argument against le-
galizing reimportation is that doing so would effectively cause
America to adopt Canada's system of price controls. Other reasons
that legalizing reimportation is not an adequate solution include the
expense of implementing a regulatory system to oversee reimporta-
tion and the difficulty of ensuring public safety. Finally, legalizing
reimportation may not solve the problem for the long term.
1. Effectively Adopting Canada's Price Controls
Legalizing reimportation would have the practical effect of adopt-
ing Canada's price controls. Two major problems arise when a coun-
try adopts another country's price controls. First, Americans
generally "do not support the idea of letting another country dictate
what prices our manufacturers can charge. '346 Secondly, adopting an-
341. Id.
342. Smith, supra note 338.
343. Id.
344. Id.
345. JOHN CALFEE, FALSE SOLUTION: WHY DRUGS FROM CANADA WON'T CUT PRICES 10
(Nov. 2002), http://www.phrma.org/publications/policy/admin/2003-07-10.771.pdf.
346. Id.
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other country's price controls does not make economic sense.
America is home to most of the leading pharmaceutical manufactur-
ers.347 The primary reason is that the United States has the most con-
ducive business environment for pharmaceutical companies, operating
in a free market pricing system that rewards innovative pharmaceuti-
cal research solutions. 348 The United States may eventually decide to
follow Canada and most of Europe and adopt price controls on
pharmaceuticals. But why should the United States just blindly adopt
Canadian price controls? If Americans in fact decide to implement
price controls, America should develop its own system-one that pre-
serves some of the incentives for pharmaceutical companies to de-
velop new treatments and medicines.
2. Expensive to Implement Effective Regulatory System
In addition to not making economic sense, another reason not to
legalize reimportation is that implementing a regulatory system to
oversee reimportation will cost the United States an enormous
amount of money.349 The FDA predicts that the first year cost of im-
plementing a regulatory program to ensure compliance with require-
ments of H.R. 2427 could be over $50 million.350 Furthermore, the
cost of the anti-counterfeiting technology required by this bill "could
raise the cost of prescription drugs by as much as $2 billion in the first
year." 351
The Congressional Budget Office (CBO) reports that if Congress
enacts H.R. 2427, it would "reduce total prescription drug expendi-
tures by about 1% or $40 billion over the 2004-2013 period. ' 352 How-
ever, the CBO report neglects to consider the cost of implementing a
regulatory program and fails to consider the cost of this bill to the
pharmaceutical industry.353 Compliance with H.R. 2427 will cost
347. See CALFEE, supra note 345, at 12. Interestingly, 45% of all new drug development in the
entire world happens in the United States. Rhonda Kay McPherson, Policy Considerations:
Medicare and Prescription Drug Coverage, 8 GEO. PUB. POL'Y REV. 25, 31 (2003).
348. Id.
349. FDA Letter to House, supra note 231, at 4.
350. Id. This cost estimate is based on a system where approximately 1000 samples would be
taken. Id. The letter notes that this estimate "could increase based on the necessary sampling
rate for the sampling that is allowed by [H.R. 2427]." Id.
351. Id.
352. H.R. 2427, The Pharmaceutical Market Access Act of 2003, supra note 317. The CBO
report goes on to say the bill would also "reduce spending on health benefits for firms that
provide health insurance. As a result, more of employees' and retirees' compensation would be
in the form of taxable income, thus increasing tax revenues. CBO estimates that H.R. 2427
would increase federal revenues by $1.5 billion over the 2004-2013 period." Id.
353. See generally id.
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pharmaceutical companies a substantial amount of money. The phar-
maceutical companies will in turn pass that cost onto consumers. Reg-
ulation of reimportation to ensure public safety will also cost the
federal government, and ultimately taxpayers, a large sum of money.
3. Public Health and Safety Problems
Another cost of H.R. 2427 is the impact on public health and safety.
Americans might pay more for their prescription drugs, but the U.S.
government contends that they enjoy the safest and highest quality
drug products in the world. 354 If enacted, H.R. 2427 would "create
serious drug safety problems. '355 HHS Secretary Tommy Thompson
explained that legalizing reimportation could "increase the flow of
counterfeit drugs, cheap foreign copies of FDA-approved drugs, ex-
pired and contaminated drugs, and drugs stored under inappropriate
and unsafe conditions." 356 He further explained, "in light of the an-
thrax attacks of last fall [2001] that's a risk we simply cannot take. '357
The FDA has no way to verify where reimported drugs were manufac-
tured, where they have been, their previous storage conditions, or that
they have not been tampered with or contaminated.35 8
In 2001, the FDA and U.S. Customs conducted a survey of im-
ported drug products entering the United States through a Carson
City, California mail facility. 359 From this survey, the FDA summa-
rized the primary risks to Americans associated with importation of
this type: "1) taking drugs of unknown origin or quality, and 2) taking
prescription drugs without prescriber supervision. '360 Perhaps the
worst public health problems are yet to come. Legalizing reimporta-
tion will open the doors to potentially huge public safety problems. 361
354. According to the Executive Office of the President, "[t]he overall quality of drug prod-
ucts that consumers purchase from licensed pharmacies in the United States is the highest in the
world and Americans can be confident that the drugs they use are safe and effective." STATE-
MENT OF ADMINISTRATION POLICY, supra note 265.
355. Id.
356. Prescription Drug Reimportation, supra note 231.
357. Id.
358. NABP POSITION PAPER, supra note 130, at 2.
359. Id.
360. Id. at 3. The Carson City survey found that officials discovered that 8% of the packages
contained drugs that were unidentifiable. Id. at 2. Several of the drugs found did not corre-
spond to FDA-approved drugs. Id. One package contained a drug that was denied FDA ap-
proval because of cardiac risks and a lack of data showing its efficacy. Id. Several shipments
contained drugs which were withdrawn from the market or controlled (illegal) substances.
NABP POSITION PAPER, supra note 130, at 2. Finally, many of the drugs which passed through
this survey were drugs intended to treat conditions properly diagnosed only by a physician and
have serious side effects and interactions with other drugs and foods. Id.
361. Id. at 1-4.
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If enacted, H.R. 2427 would greatly impede the FDA's authority and
ability to ensure the safety of prescription drugs used by Americans.
4. Reimportation May Not Solve the Problem of High Drug Prices
Legalizing reimportation might provide some immediate relief from
the high costs of prescription drugs, but it is not clear that it will pro-
vide long-term relief. One scholar, John Calfee, predicts that legaliz-
ing reimportation will backfire. 362 Calfee predicts that U.S. prices will
not drop to the current Canadian levels. 363 Instead, he forecasts that
Canadian prices will increase to almost the current U.S. levels.
364
Calfee explains, "reimportation would fail to achieve its primary goal
[of lowering pharmaceutical prices] but it would have the side effect of
upsetting our Canadian neighbors, whose health care system is perpet-
ually in fiscal crisis." 365
The reason reimportation will not have the intended effect is that
applying Canadian prices to the much larger U.S. market will set off a
chain of events, unanticipated by supporters of H.R. 2427.366 If the
United States legalizes reimportation, drug manufacturers will face
huge reductions in revenues because of drug purchases at Canada's
lower prices. 367 It will follow that American drug manufacturers then
may stop shipping drugs to Canada.368 If the manufacturers stop ship-
ping to Canada, they would lose their Canadian sales but retain
American drug sales at the higher American price.369 Canada would
then find itself without U.S. drugs and would have no choice other
than to raise their drug prices back to something close to the U.S.
prices. 370 The result would be that "our prices would go down very
little, but Canadian prices would go up a lot. '371 To make matters
worse, America would have adopted a "very strange pharmaceutical
pricing system," adopting Canada's price controls and linking the two
countries' systems of pricing pharmaceutical products.
372
362. CALFEE, supra note 345, at 10.
363. Id.
364. Id.
365. Id.
366. Id. at 11.
367. Id.
368. CALFEE, supra note 345, at 2.
369. Id.
370. Id.
371. Id.
372. Id.
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D. Price Controls on Prescription Drugs
Government initiated price controls are the most sensible solution
to the rising cost of prescription drugs. One survey indicates that 72%
of Americans support direct governmental limitations on the costs of
prescription drugs.373 The current buzz surrounding reimportation is
likely due to legislation currently under consideration and the advo-
cacy of politicians. However, while reimportation is considered a so-
lution to high drug costs, it is only fair to consider imposition of price
controls in the industry. If one consequence of legalizing reimporta-
tion is that America would effectively adopt Canada's system of price
controls, America should consider instituting its own system of price
controls.
1. Other Countries "Free-Riding" Off the Unregulated American
System
The United States is "one of the only industrialized nations in the
world where pricing in the pharmaceutical industry is unregulated. '374
Just because other countries have price controls does not mean the
United States should blindly follow. The problem, however, is that
the United States is "subsidizing European health care. '375 The phar-
maceutical industry in this country is the "undisputed world leader in
developing new and effective treatments. '376 Because almost all other
industrialized nations have price controls to keep drug costs low,
drugs cost more in America to compensate drug companies for profits
not realized abroad. All of these other countries are essentially "free-
riding" off the unregulated American system.
American citizens should not bear the burden of the development
of new and innovative drug therapies for the world. "Since most in-
dustrialized nations have implemented drug price controls, instituting
373. Stonybrook University, Health Pulse of America 2003 Survey, at http://www.sunysb.edu/
surveys/HPANov03_Pharma.htm. The Stonybrook survey also indicates that approximately two
out of every three Americans support legislative action legalizing reimportation. Id. The author
of this Comment believes that the survey is most useful to illustrate that Americans are support-
ive of any measures that will reduce the costs of prescription drugs, especially considering that
Americans changed their minds when informed about the risks of reimportation. See Ukens,
supra note 218, at 47.
374. Creech, supra note 36, at 595.
375. Martha Ann Holt, Note, International Prescription Drug Cost Containment Strategies and
Suggestions for Reform in the United States, 26 B.C. INr'L & CoMP. L. REV. 325, 326 (2003).
376. Stanton, supra note 14, at 153. Specifically, "between 1970 and 1992, American firms
accounted for 42.8% of the world's breakthrough drugs, and American firms lead in all drug
categories." Id. at 154. These numbers are striking, especially compared with Britain, which
accounts for 14%, Germany, which accounts for 7%, and France, which accounts for 3% of the
world's breakthrough drugs. Id.
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similar controls in the U.S. may simply be leveling the playing
field. '377 Instituting modest price controls, starting slightly under cur-
rent prices, will put pressure on pharmaceutical manufacturers to
streamline their businesses. Furthermore, the imposition of price con-
trols in the American pharmaceutical industry would force other
countries to bear some of the R&D burden of new and better drugs.
2. Why the United States Should Institute Price Controls in the
Pharmaceutical Industry
Although pharmaceutical companies are strongly opposed to price
controls,378 the U.S. government should implement price controls be-
cause it is the lesser of two evils. Critics argue that price controls will
"severely reduce the money available for new drug R&D. ' 379 Essen-
tially, the argument is that "the immediate financial savings to con-
sumers from limiting the price of existing pharmaceuticals will
substantially reduce the industry's incentive to innovate future ad-
vances, and its ability to fund research at current levels."
380
However, the same result would occur from legalizing reimporta-
tion. If H.R. 2427 is enacted into law, Americans will obtain increas-
ing amounts of prescription drugs from Canada. Increased sales at
lower Canadian prices and decreased sales at the higher American
prices will have the effect of slashing profits for pharmaceutical com-
panies. If it is inevitable that the industry suffers pressure against in-
novation, the federal government should choose the option giving it
the most control over the pricing of drugs. The United States should
adopt its own price controls, rather than adopting the price controls of
another country. Although it is impossible to predict the future, the
U.S. government could carefully evaluate economic factors to develop
a system of price controls that will preserve incentives for pharmaceu-
tical companies to develop new and better drugs. Furthermore, if the
United States controls drug prices, the government will have the
power to make adjustments that will help preserve the incentives for
innovation.
377. Moore, supra note 91, at 161.
378. Id. at 152-56.
379. Id. at 155.
380. Stanton, supra note 14, at 149-50. Stanton further points out that "America's over-
whelming lead in worldwide pharmaceutical innovation [is attributed] to the absence of price
regulation here." Id. at 168.
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3. Implementation of Price Controls in the United States
The first step in implementing price controls in the American phar-
maceutical industry will involve the creation of a government agency
to regulate and oversee price controls. 381 Because so many other
countries regulate drug prices, the United States can look to other
countries' successes and failures in developing its own system. 382
Since so many Americans are looking to Canada's drugs for relief
from high prices, perhaps the U.S. government should be looking at
Canada's system of price controls and Canada's PMPRB.
The government agency created to implement and oversee price
regulation in the pharmaceutical industry would ideally be "empow-
ered to set reasonable drug prices, to disseminate drug information to
the medical community, and to effect necessary remedial measures if
the agency's guidelines are not followed. ' 383 Additionally, there are
certain features that this agency must have in order to be effective. 384
It must have full access to pharmaceutical industry records, especially
confidential records of drugmakers. 385 Furthermore, this agency must
have broad power to enforce its regulations, including the power to
punish drug manufacturers in a pecuniary manner, by levying fines or
recovering excess profits.386 An effective regulatory agency will also
provide unbiased information to the public and to the medical com-
munity regarding prescription drugs as an alternative to the informa-
tion provided by pharmaceutical companies themselves. 38 7 Most
importantly, the agency should also have the power to limit drug
prices and to limit price increases to rates equal to or only slightly
above the rate of inflation. 388 The federal government must also allow
the agency to use its power to demand lower prices by "blacklisting"
drugs that it determines are priced too high, as long as comparable
alternatives exist.389
381. Pharmaceutical companies have proposed instituting "voluntary price controls" on them-
selves. Moore, supra note 91, at 166. However, "the fox should never be put in charge of the
hen house." Id. It seems clear that the most practical way to implement price controls in the
pharmaceutical industry in America would be through a government agency, rather than the
pharmaceutical industry itself. See id. at 166-69.
382. Id.
383. Id. at 167.
384. Id.
385. Moore, supra note 91, at 167.
386. Id. at 168.
387. Id.
388. Id.
389. Id.
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V. CONCLUSION
Reimportation of prescription drugs should remain illegal. By le-
galizing reimportation, the United States will invite public health di-
sasters and will be effectively adopting Canada's system of price
controls. The better solution is for the United States to join the vast
majority of industrialized nations and implement their own system of
price controls. Americans must take steps to prevent other countries
from "free-riding" off the U.S. system, which is currently free from
federal price regulations. The U.S. government cannot continue to let
other countries take advantage of the American system because
Americans cannot afford their drugs.
Until a system of federal price regulation can be implemented, per-
haps a more comprehensive Medicare prescription drug benefit and
more manufacturer discount programs will help alleviate the problem
for the short-term. However, American lawmakers should work to-
wards a long-term solution. Although the U.S. government may be
reluctant to implement federal price regulations, the government
should take steps to improve the availability of prescription drugs to
its own citizens. The federal government should take action to lower
American prescription drug prices so that millions of Americans do
not have to go without medications that will improve their health.
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